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Summary
In asthma the airways demonstrate hyperreactivity to a variety of stimuli including 
acetylcholine and histamine (Hargreave et al., 1981). The mechanism accounting for 
this heightened airway responsiveness is unknown but could be explained by an 
abnormality in airway smooth muscle function (Barnes et al., 1988).
The histamine (HI) and muscarinic cholinergic receptors, are coupled to contraction 
by the phosphatidylinositol pathway. Agonist-receptor binding results in the 
formation of the intracellular second messengers, diacylglycerol (DAG) and inositol 
triphosphate. DAG activates phospholipid-dependent, calcium-activated protein 
kinase (protein kinase C; PKC) which is thought to be involved in the sustained 
phase of smooth muscle contraction (Rasmussen & Barratt, 1984; Forder et al., 
1985; Chattergee & Tejada, 1986).
It has been suggested that the inappropriate activation of smooth muscle PKC may 
be involved in the pathogenesis of the late phase in asthma (Obianime et al., 1989) in 
which the airways remain hyperreactive to a number of endogenous agonists for a 
period of 6-12 hours after the triggering of an asthmatic attack (Cartier et al., 1982). 
This study was undertaken to examine the consequences of sustained activation of 
PKC on the reactivity of isolated rabbit and human airways.
Phorbol myristate acetate (PMA), a potent phorbol ester which can substitute for 
DAG (Castagna et al., 1982; Yamanishi et al.,1983), was used to directly activate 
PKC. The effect of incubation with PMA was examined on the contractile response 
to electrical field stimulation and to the endogenous agonists acetylcholine and 
histamine. Bronchial rings were suspended in baths containing oxygenated Krebs- 
Henseleit solution and changes in tension were measured isometrically.
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PMA (l-100|iM) potentiated cholinergic neurotransmission. The contractile response 
to electrical field stimulation (EFS) at 16Hz was increased in a concentration- and 
time-dependent manner in both human and rabbit bronchial rings, reaching a plateau 
at approximately 45-60 minutes. At this time point responses in the presence of 
PMA (10|iM) were significantly greater than in the time control tissues. In the 
rabbit preparation both control and potentiated responses were abolished by atropine 
(0.1 pM). Potentiation was absent after incubation with the calcium channel blocker 
verapamil (lOpM) and reduced after the putative PKC inhibitors H7 (lOfiM) and 
staurosporine (0.5pM).
At 45 minutes into incubation, PMA (lOpM but not lflM) significantly enhanced the 
contractile response of rabbit bronchi to individual concentrations of ACh (0.1- 
30|iM) within a cumulative ACh concentration response curve (0.01-300pM). 
There was a small leftward shift in the curve but no increase in the maximum 
response to ACh. The enhancement is thus of the type that would be expected of a 
synergism taking place beyond the receptor, rather than an increase in sensitivity of 
receptors. Repeating the experiment in a low calcium environment produced a 
rightward shift in control responses which was not seen in PMA-incubated tissues, 
indicating that PMA may produce an increase in the sensitivity of the preparation.
Against sequential responses (at 15 minute intervals starting 45 minutes into the 
incubation period) to a single sub-maximal concentration of Ach (lOjiM), PMA 
(lOpM but not lpM) significantly enhanced the first response in rabbit and human 
bronchi but the second and subsequent responses were not significantly greater than 
time controls. In the rabbit preparation the increase in response to ACh was inhibited 
by the calcium channel blockers nifedipine (0.3pM) and verapamil (lOpM), 
implicating calcium influx via voltage-dependent channels in the response, and 
attenuated by amiloride (100pM), an inhibitor of Na+/H+ exchange. In contrast to 
their effects versus EFS, the protein kinase-C antagonists H7 (10pM) and
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staurosporine (0.5pM) did not prevent the PMA-induced potentiation of response to 
ACh. The cyclo-oxygenase inhibitor indomethacin (lOpM) had no effect on the 
PMA-induced potentiation of response but itself produced a small but significant 
increase in response to ACh indicating an ongoing inhibitory influence of a cyclo- 
oxygenase product versus neurotransmission and/or contraction.
The response of rabbit bronchial smooth muscle to a submaximal concentration of 
histamine (10|iM) was also significantly increased during incubation with PMA, 
indicating that PMA may induce a change in intracellular coupling rather than an 
effect on (two sets of) receptors. Following washout in fresh Krebs second and third 
responses remained elevated.
These results demonstrate that PMA can cause increased reactivity of rabbit and 
human airway smooth muscle to cholinergic nerve activation and to stimulation by 
ACh and histamine. They suggest that phorbol ester-induced activation of PKC is 
responsible, and that the potentiation of response is mediated, at least in pan, by 
increased fluxes of calcium and sodium ions and is independent of prostaglandin 
production. The findings, therefore, support the hypothesis that sustained activation 
of PKC in vivo could contribute to airway hyperreactivity to contractile stimuli.
Sections 1-4
INTRODUCTION
1.1 Asthma
Asthma is a reversible, obstructive disease characterised by increased responsiveness 
of the airways. It is one of the most common chronic diseases in industrialised 
countries and there is evidence that the prevalence and severity are increasing (Ayres, 
1986; Fleming, 1987). Despite advances in therapy, asthma deaths in the 5- to 34- 
year-old age group have risen over the last decade in the UK by an average of 4.7% 
per annum, at a time when mortality from most other treatable diseases is declining 
(Burney, 1986, 1987).
1 2  Bronchial hyperreactivity
A cardinal feature of asthma is the hyperreactivity of the airways to a wide variety of 
stimuli that do not produce this response in non-asthmatic subjects. Bronchial 
hyperreactivity is virtually universal in asthma and the extent of this hyperreactivity 
seems to correlate well with the clinical severity of the condition (Cockcroft et al.,
1977). In the absence of a "gold standard" test for asthma (the disease shares several 
characteristics with chronic bronchitis and emphysema), tests of bronchial 
hyperreactivity have often been employed (ATS committee report, 1962). In their 
review of allergic asthma, Jacobs and Kaliner (1989) conclude that the presence of 
airway hyperreactivity is necessary for asthma to develop but that it is not itself 
sufficient to produce asthma. Although the precise cause of the hyperreactivity is not 
known it is likely that there is no single factor and that several interact to produce the 
effect. Possible mechanisms postulated to produce an increase in reactivity include an 
alteration in the "normal" neural pathways or in the epithelium or smooth muscle of 
the airways.
The degree of hyperreactivity is not constant and may increase after upper respiratory 
tract viral infections (Empey et al., 1976) or after exposure to air pollutants
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(Holtzman et al., 1979) or allergens (Boulet et al., 1983). Recent studies have 
suggested that inflammation may play an important role in the development of 
bronchial hyperreactivity via the interaction of inflammatory cells, mediators and 
nerves with the components of the airway wall (Barnes, 1989). Histopathologic 
examination of the airways of asthmatic subjects show a marked airway 
inflammation, with an infiltration of inflammatory cells, particularly eosinophils. 
These cells, along with neutrophils and platelets, have been implicated in the 
modulation of bronchial hyperreactivity (Nadel, 1984; Chung, 1986). Neutrophil and 
eosinophil products have recently been shown to increase airway responsiveness in 
isolated human bronchial tissue (Hallahan et al., 1990).
A wide range of inflammatory mediators have been implicated in the pathogenesis of 
bronchial hyperreactivity, and of asthma, including histamine, prostanoids, 
leukotrienes, PAF, adenosine, bradykinin, and sensory neuropeptides. These 
mediators produce their effects by activating specific cell surface receptors which are 
localised to a variety of cells. Receptor activation may result in contraction of airway 
smooth muscle, mucus and fluid secretion, microvascular leakiness, chemotaxis of 
inflammatory cells and neuronal activation (Barnes, 1987). The mucus 
hypersecretion and increase in vascular permeability results in oedema and exudation 
of plasma. The resultant mucosal thickening leads to a narrowing of the airways, 
altering the airway geometry such that the same degree of constriction produces a 
greater narrowing of the airway lumen (Moreno et al., 1986).
Epithelial damage is a prominent feature of asthma and is implicated in the 
development of bronchial hyperreactivity. Both the common cold and the influenza 
virus damage the airway epithelium and can produce hyperreactivity to histamine or 
methacholine (Empey et al., 1976). Epithelial damage can also be caused by 
mediators released from the inflammatory cells commonly found in asthmatic 
airways. Eosinophils secrete a variety of toxic substances including major basic
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protein (MBP) which causes death and shedding of epithelial cells (Gleich et al., 
1988). Oxygen-derived free radicals produced by neutrophils are similarly toxic to the 
epithelium.
Epithelial damage is important as this cell layer performs a variety of essential 
functions. As well as its role in mucociliary clearance and the provision of a physical 
barrier against noxious agents, the epithelium modulates the environment of the 
underlying smooth muscle via the metabolism and regulation of mediators and the 
production of relaxant, constrictor or chemotactic factors. Damage to the epithelium 
may also expose the underlying sensory nerves which may result in exaggerated 
vagal reflex reactions. It is also possible that functional biochemical abnormalities 
may be present in the epithelial cells of asthmatics resulting in the characteristic 
bronchial hyperreactivity (Cuss & Barnes, 1987).
An imbalance in the neural control of smooth muscle, an increase in excitatory input 
(cholinergic or a-adrenergic) or conversly a decrease in inhibitory (b-adrenergic or 
non-adrenergic non-cholinergic (NANC)) input to airway smooth muscle, could 
result in an increased reactivity of the airways. Inflammatory mediators may influence 
neurotransmitter release from airway nerves and conversely neurotransmitters may be 
pro-inflammatory (Barnes, 1989a). Similarly, neuropeptides in capsaicin-sensitive 
sensory nerves, such as substance P, have potent pro-inflammatory effects. If these 
are released by an axon reflex, they may amplify the inflammatory response in asthma 
(termed neurogenic inflammation; Barnes et al., 1990).
Although any one of these mechanisms may dominate in a particular situation it seems 
unlikely that a single mechanism will explain the cause of airway narrowing in every 
case. Rather, it is more likely that the hyperreactivity results from an interplay of 
several of the above mentioned mechanisms and the underlying smooth muscle.
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Smooth muscle hypertrophy or hyperplasia is common in asthmatic airway (Dunnil et 
al., 1969; Heard & Hossain, 1973) and while the increased amount of muscle can 
exert a greater degree of force and therefore constriction, a more significant change 
may be in the cell-to-cell signalling or excitation-contraction coupling mechanisms at 
the intracellular level.
Possible defects in smooth muscle that could result in hyperreactivity include a 
change in the number of gap junctions, altered nervous control or a change in the 
number of receptors, altered excitation-contraction coupling or an increased 
sensitivity of the contractile proteins themselves. Similarly, that asthmatic airways 
show an exaggerated response to a variety of different spasmogens utilizing many 
different receptors suggests that the possible abnormality lies beyond the receptors, in 
the smooth muscle itself. It is possible that there is a change in the regulation of 
contraction/relaxation in the smooth muscle. Alternatively there could be an enhanced 
coupling of many receptors, perhaps by an alteration in phospholinositol hydrolysis, 
a system which is utilised in excitation-contraction coupling of many of the receptor 
systems in smooth muscle (Barnes, 1987). A defect in this, final, pathway of 
contraction provides a possible mechanism for the non-specific bronchial 
hyperreactivity of asthma.
This project was undertaken with the funding of the National Asthma Council to 
study the role of protein kinase C, an integral component of the phosphotidyl inositol 
pathway, in the development of bronchial hyperreactivity, in animal and in human in 
vitro preparations.
Section 2
CHARACTERISTICS OF THE BRONCHI
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2.1 Nerve supply to the bronchi
All the nerves leading to the trachea and bronchi are made up of a mixture of afferent 
and efferent fibres, a parasympathetic supply from the vagus and a sympathetic 
supply from the neighbouring sympathetic chain. On entering the lung the fibres 
become entwined in a plexus behind the hilum of each lung, from which nerve fibres 
distribute to the airways. Neural control is especially important in the 4-7th (medium­
sized) bronchi which have a denser innervation than either the trachea or the periphery 
(Daniel et al., 1986). In a systematic electron micrograph study of bovine tracheal 
smooth muscle Cameron & Kirkpatrick (1977) reported an axon/muscle cell ratio of 
1/28. None of the nerves came within 200nm of the muscle and discounting those 
further than lOOOnm away they obtained a ratio of 1/90. In medium-sized bronchi the 
density of nerve supply is approximately twenty times that of the trachea, i.e. 18 
axons per 100 muscle cells (Daniel et al., 1986). Nerve bundles are found in trachea 
and in the bronchiolar regions but the alveoli are also innervated. The bundles run 
mainly within the intramuscular septa rather than in the muscle itself, and are arranged 
parallel to the muscle (Gabella, 1989).
Ganglia lie outside the smooth muscle layer in the bronchial wall. Their complex 
structure includes several types of neuronal bodies including cholinergic, adrenergic 
and non-adrenergic non-cholinergic (NANC) elements, which interact to integrate and 
coordinate the neural input to smooth muscle (Cobum, 1987; Dey et al., 1981).
Cholinergic innervation
The principal input, and main excitatory input, to the lungs is cholinergic 
(Widdicome, 1963; Foster, 1964). The non-myelinated post-ganglionic cholinergic 
fibres may be activated reflexly by sensory receptor stimulation or pre-junctionally by 
inflammatory mediators. Muscarinic receptors are found principally in central airways
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and rapidly decrease in number towards the periphery (Barnes et al., 1983). They 
have been subdivided pharmacologically into M! (neuronal), M2  (cardiac) and M3 
(glandular & smooth muscle) subtypes. Mi receptors are located on airway ganglia 
where they may have a facilitatory effect on ganglion neurotransmission (Lammers et 
al., 1989). Pre-synaptic M2  autoreceptors on nerve terminals inhibit release of ACh 
(Minette & Barnes, 1988) and the smooth muscle M3  receptors mediate contraction 
(Barnes, 1989b).
Adrenergic innervation
A small alpha-adrenergic excitatory effect can be seen in the rabbit in vivo (Mustafa et 
al., 1982) and in human tracheal smooth muscle in vitro (Kneussel & Richardson,
1978). Adrenergic fibres are scarce in the bronchi of rabbit (Mann, 1971) and human 
(Pack & Richardson, 1984; Laitinen, 1985) but are abundant in bronchial muscle of 
cat and dog (Silva & Ross, 1974; Knight et al., 1980). Some adrenergic fibres are 
closely associated with cholinergic nerves or terminate on parasympathetic ganglia 
and may modulate the transmission via a2-adrenoceptor effects (Jacobowitz et al., 
1973; Knight et al., 1980; Daniel et al., 1986). Mammalian lung has a high density 
of p-receptors and these increase in density from the trachea to the terminal 
bronchioles (Barnes et al., 1983). Autoradiographic techniques indicate that only p2- 
receptors are present on human airway smooth muscle and this subspecies mediates 
all relaxation of central and peripheral airways in vitro (Carstairs et al., 1985; Goldie 
et al., 1984). However, adrenergic blockade has no effect on the inhibitory 
component of the response of human bronchial to EFS in vitro, indicating that there is 
no functional sympathetic innervation of smooth muscle (Doige & Satchell, 1982; 
Richardson & Beland, 1976; Davis et al., 1982). Subsequent immunohistochemical 
studies confirmed this supposition, showing that no adrenergic nerve terminals 
terminated in smooth muscle (Partanen et al., 1982; Sheppard et al., 1983). In
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guinea-pig airways adrenoceptor-mediated relaxation is seen in the trachea but not in 
the bronchus or bronchi (Doige & Satchell, 1982; Grunstrom et al., 1981).
NANC innervation
A second inhibitory component reaches the airways via the vagus nerve and is present 
mainly in proximal airways. This NANC response has been demonstrated in guinea 
pig (Cobum & Tomita, 1973; Coleman & Levy, 1974) and in human (Richardson & 
Beland, 1976) and is the principal inhibitory pathway in human airways (Barnes, 
1986a).
The principal candidate for mediation of the NANC inhibitory response is VIP, a 
potent relaxant of human smooth muscle (Palmer et al., 1985a). VIP receptors have 
been localised to airway epithelium, submucosal glands and smooth muscle (Barnes 
& Carstairs, 1986). The density of VIP-containing nerves diminishes in the small 
airways (Dey et al., 1981) and ultrastmctural studies suggest that VIP may co-exist in 
the same nerve terminals as ACh (Schultzberg et al., 1982). A second peptide, 
peptide histidine isoleucine (PHI), has also been implicated in the NANC response, 
shares an identical distribution in the airways with VIP (Lundberg et al., 1984) and is 
possibly released with VIP. A related peptide, peptide histidine methionine (PHM), 
has been found in human airways and may mediate the NANC response in man.
NANC excitatory nerves containing substance P, calcitonin gene related peptide and 
other tachykinins have been identified in human and animal airways (Barnes, 1986b) 
and receptors for substance P have been localised to smooth muscle and submucosal 
glands (Carstairs & Barnes, 1986). The release of tachykinins upon sensory nerve 
stimulation suggests a possible involvement in local axon reflexes.
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Afferent nerves
Afferent fibres are carried in the vagus from sensory receptors in the surface 
epithelium and submucosa including rapidly adapting cough and irritant receptors, 
slowly adapting stretch receptors and juxtacapillary receptors deep in the lung. These 
fibres may mediate an axon reflex, which can be induced in human bronchi in vitro 
(Lundberg et al., 1983), resulting in smooth muscle contraction and an increase in 
vascular permeability.
2.2 Neural control o f the bronchi
The degree of neural control of the bronchi varies considerably between species. The 
smooth muscle may be organised as a multi-unit structure, with a very dense 
innervation and many nerve fibres per muscle cell, or as a single-unit structure which 
has good electrical coupling via many gap junctions, allowing simultaneous 
contraction of blocks of muscle fibres, and has spontaneous oscillations of membrane 
potential. Gap junction connections are seen in human airways (2.7 junctions per 
100 muscle cells; Daniel et al., 1986). However the smooth muscle is only sparsely 
innervated and has no spontaneous activity (Stephens et al., 1986; Cameron & 
Kirkpatrick, 1977) and may therefore be considered an intermediate structural type, 
neither multi- nor single-unit.
The number and size of gap junctions can change with stimulation and with time, 
within minutes in human tracheal smooth muscle in vitro (Daniel et al., 1986; 
Kroeger & Stephens, 1975; Kannan & Daniel, 1978). Such a structural change in 
vivo could be important in the development of bronchial hyperreactivity as movement 
from a multi- to a single-unit structure would increase the excitability of airway 
smooth muscle.
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2.3 Musculature
The muscular system of the lung is entirely composed of smooth muscle (Fig. 2.1), 
which can be divided into three morphological groups: (tracheo)bronchial, pulmonary 
and interstitial.
The course and location of tracheal muscle differs according to the species and the 
region of the trachea examined. In man muscle is only seen in the membranous part 
for most of the length of the trachea, where strong muscle bundles of approximately 
300-400 cells each (Stephens, 1988) connect the dorsal ends of the tracheal 
cartilages, but near its bifurcation annular (ring-like) muscles surround the entire 
circumference. This differs from the arrangement in dog where the trachea is 
surrounded by strong annular muscles over its entire length. The insertion of muscle 
on the cartilage is internal in man but external in the rabbit. External to the layer of 
muscle of the membranous part of the trachea is a small quantity of longitudinal 
muscle.
The bronchi are defined as those airways that have cartilage in their walls. Bronchial 
muscle is situated in the airway wall from the main bronchi to the terminal 
bronchioles. In man the muscles of the main bronchi are somewhat similar to those of 
the inferior portion of the trachea; thus the lumen becomes smaller mainly due to 
contraction of the muscle of the membranous part. As the bronchi get smaller the 
muscle changes its course from annular to spiral and this tendency is increased in the 
more peripheral regions. The smooth muscle cells are spindle shaped, approximately 
1000pm long and 5-10pm at the widest part. They have a single, central, cigar­
shaped nucleus and are unbranched, unlike those of the membranous part of the 
trachea which may have branches and anastomoses. The smooth muscle is arranged 
in spiral strands around the airway and completely encircles the bronchi internal to the 
cartilagenous plates. The larger bronchi have two sets of smooth muscles, opposing
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Figure 2.1 The Musculature of the Airways, 
(from Nagaishi et al., 1972)
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right and left spirals, surrounded by elastin and collagen and with nerve fibres and 
blood vessels running in the connective tissue between the strands. Contraction of 
these muscles results in the narrowing and shortening of the airway. In the peripheral 
bronchi the mucus membrane may produce shelf-like folds during muscle 
contraction. When the contraction of the muscle becomes stronger, the formation of 
folds becomes even more evident, the surfaces of the membrane folds touch each 
other and the circulation of air may be suspended temporarily.
Pulmonary muscle refers to muscles which are distributed in alveolar regions. From 
the respiratory bronchiole to the alveolar duct the muscle spirals become elongated, 
and in the more peripheral regions near the alveoli the muscle is net-like and 
surrounds the alveolar rings in a sphincterlike formation. This arrangement of 
muscles has been termed a "geodesic network" (Nagaishi et al., 1972; shortest 
distance between two points on a spherical surface).
2.4 Electrical Properties o f smooth muscle
Airway smooth muscle cells respond to neurotransmitter substances, bronchoactive 
autocoids or depolarisation by KC1 with a graded increase in membrane potential 
rather than by producing spike depolarisations, indeed many mediators produce a 
contraction without significantly changing the membrane potential (Bolton, 1979; 
Middleton, 1984). Under normal conditions no spontaneous electrical activity is 
observed. This electrical quiescence is due to voltage-sensitive potassium channels 
which act to stabilize the membrane potential. As the muscle depolarises, these 
channels open thereby increasing membrane potassium conductance and limiting 
further depolarisation. There is evidence for the presence of at least two types of 
voltage-sensitive delayed rectifier potassium channels in the canine airway smooth 
muscle cell (Kotlikoff, 1987, 1989). Voltage-activated calcium channels will also 
open when the cell is depolarised from its resting potential but the depolarisation that
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attends this inward current is blunted by the almost simultaneous activation of the 
outward currents. Unless the rise is tightly compartmentalised, it is likely that 
calcium-activated potassium channels are also activated whenever the cytosolic 
calcium concentration rises (Kotlikoff, 1989). Electrical activity is increased when 
rectification is reduced by potassium channel inhibitors such as tetra-ethylammonium 
(TEA; Tomita, 1989).
Depolarisation is conducted through the muscle bundle with relatively little 
decrement, thus changes in membrane potential are conducted down the preparation 
by cable-like spread (Kirkpatrick, 1981). The small amount of depolarisation may be 
sufficient to intitiate the contractile process as the membrane need only be depolarised 
by 5mV before contraction (Suzuki et al., 1976).
Although tracheal smooth muscle generally has a relatively low level of excitability, 
the degree of spontaneous activity varies between species and even within species 
with location in the bronchial tree. Canine trachea, a commonly used preparation in 
electrophysiological studies, has a stable membrane potential of approximately -54 to 
-60mV (Farley & Miles, 1977; Kannan et al., 1983; Kroeger & Stephens, 1975) 
while the membrane potential of the bronchi is reported to be 3mV higher (Souhrada 
et al., 1983). In contrast, human tracheal smooth muscle has a higher muscle tone 
and degree of rhythmic electric activity, consisting of oscillatory fluctuations of 
membrane potential (slow waves). Tracheal smooth muscle strips obtained from 
autopsy had a resting potential of -45mV and exhibited slow waves with a frequency 
of 19.7 waves per minute (approximately 0.3Hz) and an amplitude of 7.7mV (Honda 
& Tomita, 1987). Slow waves are converted to spikelike action potentials when 
rectification is reduced by TEA (Kroeger & Stephens, 1975; Kannan et al., 1983). 
Tone and activity seem to be related and both are likely to be produced by 
endogenous arachidonate derivatives: prostaglandins in the guinea pig and 
leukotrienes in Man (Tomita, 1989).
Section 3
CONTRACTION OF 
AIRWAY SMOOTH MIJSCLR
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3.1 Contraction o f bronchial smooth muscle
Smooth muscle cells contain the contractile proteins actin, myosin and tropomyosin. 
The contractile elements are the same as those of striated muscle (although lacking in 
troponin), but the amount of myosin present in airway smooth muscle is only a fifth 
of that in striated muscle and the relative proportion of the two proteins is different 
(approximately 13 actin to 1 myosin instead of 6  to 1; Dillon & Murphy, 1982).
The actin filaments form a helix of 2 thin polymer chains. Myosin is a thicker filament 
made up of two heavy chains (200,000 Da each) and two pairs of light chains (one 
pair each of 17,000 and 20,000 Da) forming the head of the molecule (Rodger, 
1988). Although the contractile elements of airway smooth muscle are not arranged 
in regular sarcomeres as in skeletal smooth muscle, individual myofibrils are striated 
and electron micrographs of airway smooth muscle show the presence of dark bands 
in the sarcolemma. Actin is attached to the cell membrane at these points and also to 
similar structures in the cytoplasm known as dense bodies (Stephens, 1987). Somylo 
et al. (1984) have suggested that these structures are not haphazardly arranged but 
that they show periodicity and can be regarded as analogous to the Z-bands of striated 
muscle. The contractile elements lie in parallel and crossbridges may be seen 
connecting the strands of actin and myosin. It is possible that the basic mechanism of 
contraction is similar in both striated and smooth muscle and that the sliding filament 
model of Huxley and Neidergerke (1954) may be applicable to smooth muscle. 
According to this theory, actin is actively transported along the myosin molecule by 
attachment, flexion and detachment of the myosin head.
In striated muscle this process is regulated by calcium. The interaction of actin and 
myosin is inhibited by troponin via its effect on the location of tropomyosin on the 
thin filament. The binding of calcium to troponin results in a change in the structure
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of the thin filament (Squire, 1981), the interaction of actin and myosin, hydrolysis of 
ATP and the movement of actin past myosin.
Similarly, contraction in non-striated muscle is regulated by calcium. While smooth 
muscle does not possess troponin, tropomyosin and caldesmon may play similar role 
in the regulation of actin (de Lanerolle, 1989). The important reaction in the 
regulation of smooth muscle contraction appears to be the phosphorylation of the 
20kDa subunits of myosin light chain (MLC) which stimulates the actin activated 
Mg2+ATP-activity of the myosin (Sobieszek, 1977) (see below) unlike striated 
muscle which is regulated by the actin-linked troponin-tropomyosin system.
3 2  Control of smooth muscle contraction.
The state of activation of the airway smooth muscle cell is controlled by two calcium- 
dependent mechanisms which are activated by receptor occupation.
Agonist binding at membrane receptors results in the cleavage of inositol 
phospholipids into two second messengers, diacylglycerol (DAG) and inositol 
triphosphate (I-l,4,5-P3), by membrane-bound phospholipase C (section 4.1). I-
1,4,5-P3  releases calcium from intracellular stores while DAG activates protein kinase 
C (PKC) (Castagna et al., 1982; Nishizuka, 1986). The I-l,4,5-P3-induced release 
of calcium is important in the immediate, transient response to agonist-receptor 
binding whereas it is thought that activation of PKC is involved in the sustained 
phase of the subsequent contraction (Rasmussen & Barratt, 1984; Forder et al., 
1985; Chattergee & Tejada, 1986). Neither second messenger alone is sufficient for 
complete signal transduction and it has been shown in several tissues that calcium 
mobilization and activation of PKC act synergistically to produce the full 
physiological response (Yamanishi et al., 1983; Nishizuka, 1984 & 1986; Baraban et 
al., 1985; Park & Rasmussen, 1985).
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The signal initiating contraction in smooth muscle appears to be the I-l,4,5-P3- 
induced rise in the intracellular calcium concentration ([Ca2+]i). When the [Ca2+]i 
rises from resting levels of approximately 0. IjiM into the lfiM range, the free Ca2+ is 
bound by calmodulin (CaM) which is fully activated by the binding of 4 molecules of 
Ca2+. MLC inhibits the actin-activated ATPase activity and this inhibition is released 
by its phosphorylation to MLC-P by myosin light chain kinase (MLCK) which 
requires Ca2+4-CaM for activity (Adelstein & Klee, 1981; Dabrowska et al., 1978). 
MLC-P can interact with actin resulting in the activation of the ATPase in the myosin 
headgroup. Hydrolysis of ATP to ADP provides energy for the flexion of the myosin 
head and the subsequent filament movements result in contraction of the smooth 
muscle. Relaxation is brought about by cessation of stimulation, resequestration of 
calcium and dephosphorylation of the MLC by a specific phosphatase system.
The dependence of contraction on MLC phosphorylation was shown in in vitro 
studies on canine tracheal smooth muscle (de Lanerolle & Stull, 1980). The peak in 
MLC phosphorylation was later demonstrated to precede the generation of maximum 
force and the force generated by a smooth muscle was shown to be related to the 
level of phosphorylation (de Lanerolle et al., 1982; Silver & Stull, 1982; Kamm & 
Stull, 1985).
Use of skinned muscle preparations allowed the investigators to manipulate the ionic 
and protein environment of the contractile and regulatory proteins while measuring 
the tension and protein phosphorylation. Such experiments provided evidence 
strongly suggesting that MLCK-stimulated phosphorylation of MLC is an essential 
prerequisite for smooth muscle contraction (Cassidy et al., 1979; Hoar et al., 1979; 
Kerrick et al., 1980).
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3.3 Mechanism of force maintenance in smooth muscle
While the above mechanism of initiation of force generation is widely accepted there 
is much debate on the mechanism of force maintenance. This was initiated by the 
observation, in arterial smooth muscle, that force can be maintained despite the 
dephosphorylation of myosin to almost resting levels (Dillon et al., 1981). This 
finding was substantiated by Aksoy et al. (1982 & 1983), Silver & Stull (1982) and 
Kamm & Stull (1985) who demonstrated that, following initiation of contraction, 
MLC phosphorylation frequently decreases over prolonged stimulation despite the 
fact that steady-state tension is maintained. However, this dephosphorylation was not 
observed by several other groups (Kong et al., 1984; de Lanerolle & Stull, 1980; de 
Lanerolle et al., 1982; Gerhoffer, 1986) who found a good correlation between MLC 
phosphorylation and sustained tension. This apparent anomaly lead to the formation 
of several hypotheses to explain the biochemical basis of steady state force 
maintenance
On the basis of their observations in vascular smooth muscle, Murphy and co- 
workers suggested that a special actomyosin crossbridge (latch bridge) is functional 
in the maintained phase of contraction (Dillon et al., 1981). According to the latch 
bridge hypothesis, the crossbridges are initially of the normal rapidly-cycling type but 
2—5 seconds into the contraction (Dillon et al., 1981; Stephens et al., 1986) these are 
replaced by very slowly-cycling latchbridges which are much more efficient, utilizing 
only a quarter of the energy expended by the rapidly-cycling crossbridges (Seigman 
et al., 1980). Oxygen uptake falls to 3-4 times less than in the initial phase (Stephens 
et al., 1986; Seigman et al., 1980). While the ability to shorten has fallen to almost 
zero, the ability to develop force is maximal in this state (Dillon et al., 1981). It is not 
clear whether these latch bridges represent a discrete population or are simply 
converted from normal cross bridges.
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There are, therefore, two discrete bodies of data, the first suggesting a close 
correlation between myosin phosphorylation and force, and the second demonstrating 
force maintenance in the face of myosin dephosphorylation. The evidence for each of 
these hypotheses was examined by de Lanerolle (1989) who reviewed the data 
supporting each mechanism. However, as this author pointed out, there is no reason 
to assume that the same regulatory system is operating in all smooth muscles and the 
most convincing evidence for the existence of latch bridges has come from work in 
vascular smooth muscle.
An alternative regulatory mechanism was suggested by Rasmussen and coworkers 
(1987) in which the sustained response is largely due to the phosphorylation by PKC 
of structural and regulatory components of a fibrillar domain. This hypothesis is 
based on ultrastructural studies which showed two spatially different fibrillar domains 
in mammalian smooth muscle cells (Small et al., 1986; Furst et al., 1986). The first 
of these consists of actin and myosin filaments and their associated proteins. The 
second contains filamin (and other actin-binding proteins), actin, and desmin (and 
other intermediate filament proteins e.g. synemin) and is referred to as the F-A-D 
domain. According to their hypothesis the latch mechanism is caused by a 
"reorganisation and stablisation of the supramolecular organisation of the components 
of the F-A-D domain". They suggest that phosphorylation by activated PKC of late 
phase proteins (desmin, synemin, caldesmon and several unspecified cytosolic 
proteins) leads to the stabilisation of the F-A-D protein domain in a new configuration 
such that it is maintained even when MLC-P is dephosphorylated.
3.4 Role o f PKC in sustained responses
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While activation of PKC is central to the fibrillar domain hypothesis (Rasmussen et 
al., 1987), it may also be important in the other models of force maintenance as both 
MLC and MLCK have been shown to be substrates for PKC (Nishikawa et al.,
1983). PKC phosphorylates MLC at a site distant from that of MLCK. Each enzyme 
incorporates two moles of P 04 per mole myosin; sequential phosphorylation of MLC 
by MLCK and PKC can occur resulting in the incorporation of four moles P 0 4 per 
mole myosin (Nishikawa et al., 1983). These sequential reactions are known to 
decrease the activity of the actomyosin ATPase. Thus activated PKC may modulate 
the activity of smooth muscle myosin.
PKC has previously been proposed to be involved in the maintenance of sustained 
contraction and has been found to phosphorylate (in vitro) the actin-binding proteins 
vinculin and filamin as well as smooth muscle MLC and MLCK (reviews: Nishizuka, 
1986; Abdel-latif, 1986). It has also been suggested that PKC increases the affinity of 
the contractile proteins for calcium (Rodger, 1986) and that it might therefore be 
directly involved in the maintained tension phase of airway smooth muscle 
contraction via its action on the contractile apparatus.
Chattergee and Tejada (1986) showed that phorbol esters, substances which activate 
PKC (section 4.5), induced stress in vascular smooth muscle that was not 
proportional to MLC phosphorylation and was not preceeded by high levels of MLC 
phosphorylation. The responses were obtained at concentrations that were too low 
alone to support stress of MLC phosphorylation and this high calcium sensitivity, 
coupled with the dissociation between maintained tension and MLC phosphorylation, 
make PKC a potential candidate for involvement in the latch state.
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An alteration in the distribution, quantity or activity of PKC in airway smooth muscle 
could, therefore, have a significant effect on the ability of the muscle to maintain 
tension. Inappropriate or excessive activation of PKC might play a significant role in 
the degree and duration of bronchoconstriction. Wi$h the integral role of the enzyme 
in cell signalling (section 4) it is clear that many signals focus on PKC and it is 
possible that deviation from its normal pattern of activation could be a contributing 
factor to hyperreactivity in bronchial smooth muscle.
Section 4
SECOND MESSENGERS AND 
PROTEIN KTNASE C
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4.1 Calcium-mobilising Receptors
The muscarinic cholinergic receptor and the histamine receptor are among a group of 
receptors, collectively termed calcium-mobilising receptors, which are linked to 
phosphoinositide turnover. This group has over 25 members (Michell, 1982) and 
includes receptors for neurotransmitters, hormones and growth factors. In airway 
smooth muscle contractions induced by acetylcholine, histamine and serotonin are 
related to phosphatidylinositol breakdown (Barnes et al., 1986). The involvement of 
inositol phospholipids in receptor mechanisms was first described in two papers by 
Mabel and Lowell Hokin appearing in 1953 and 1954 which showed a marked 
turnover of phosphatidylinositol (PI) on activation of muscarinic cholinergic receptors 
(reviewed: Hokin, 1987).
Binding at a calcium-mobilizing receptor stimulates the hydrolysis of inositol 
phospholipids by phospholipase C (Michell, 1975). This has been shown in 
membrane preparations to be dependent on GTP (Litosh et al., 1985), suggesting that 
a G protein(s) is involved in regulating enzyme activity. Conversion from the inactive 
(GDP) state to the active (GTP) state is dependent on receptor occupancy. 
Phosphatidyl inositol 4,5-bisphosphate (PI-4,5-P2) is hydrolysed by phospholipase 
C to inositol 1,4,5-trisphosphate (I-l,4,5-P3) andsrt-l,2-diacylglycerol (DAG; Fig. 
4.1). These molecules act as second messengers and function as two arms of a 
bifurcating signal pathway (Fig. 4.2). I-l,4,5-P3 is released into the cytosol where it 
functions to release calcium from the endoplasmic reticulum (reviewed: Berridge, 
1984; Berridge & Irvine, 1984). DAG remains in the membrane and activates protein 
kinase C. Neither of the second messengers is sufficient for complete signal 
transduction and it has been shown in several tissues that calcium mobilization and 
activation of PKC act synergistically to produce the full physiological response 
(Yamanishi et al., 1983; Nishizuka, 1984 & 1986; Baraban et al., 1985; Park & 
Rasmussen, 1985).
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Figure 4.1
Schematic diagram of the molecular structure of phosphatidylinositol 4,5- 
bisphosphate showing line of cleavage to form inositol 1,4,5-trisphosphate and 
diacylglycerol.
(from Baron, 1989)
34
Agoni s t
Phosphatidyl ser ine
d a g -:-:-:.: ‘X - - P J P 2f  g  j------------${ phospholipaseC proteinkinase  C
I - 1 A 5 - R
Calcium/ 
Calmodulin 
Kinase
protein
( inact ive)
protein  
( inact ive)
phosphorylated
protein
(ac t i ve )
phosphorylated
protein
(ac t ive )
? membrane channel s  ?
? c on t r ac t i l e  
apparatus ?
i
CONTRACTION
Figure 4.2
Schematic diagram of the intracellular coupling of calcium mobiliising receptors.
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4.2 Inositol trisphosphate
Cholinergic stimulation of isolated membranes causes hydrolysis of PI, PI-4-P and 
PI-4,5 -P2  (Dunlop & Malaisse, 1986). Hydrolysis of PI-4,5-P2 has been reported in 
airway smooth muscle (Takuwa et al., 1986; Baron & Cobum, 1987) and production 
of I-l,4,5-P3 and other phosphates has been observed in smooth muscle from bovine 
and canine trachealis smooth muscle (Grandordy et al., 1986; Takawa et al., 1986; 
Baron & Cobum, 1987; Baron et al., 1989).
I-l,4,5-P3 mediated release of Ca2+ from internal stores has been demonstrated in 
canine tracheal smooth muscle (Hashimoto et al., 1985). The common method 
employed to study calcium mobilization involves the addition of I-l,4,5-P3 to 
permeabilized cells followed by measurement of the increases in fluorescence of the 
Ca-sensitive drugs quin-2 or fura-2, or efflux of Ca2+ (Suematsu et al., 1984; 
Somylo et al., 1985; Goldman et al., 1986).
Ca2+ is constantly cycling across the endoplasmic reticulum membrane; the passive 
efflux is balanced by ATP-dependent pumping of Ca2+. The electrogenic potential 
created by the active uptake of Ca2+ is balanced by passive efflux of potassium, 
which re-enters via K+/C1- co-transport (Prentki et al., 1984).
Ca2+ release is preceded by the binding of I-l,4,5-P3 to a specific receptor present 
on some but not all of the endoplasmic reticulum (Spat et al., 1986). There appear to 
be distinct I-l,4,5-P3-sensitive and insensitive compartments within the endoplasmic 
reticulum and it is likely that the I-l,4,5-P3 -sensitive pool is localized to a region 
close to the cell surface (Biden et al., 1986). Only about 50% of the calcium stored in 
the endoplasmic reticulum is able to be released by I-l,4,5-P3 (Muallem et al., 1985) 
and this appears to be accomplished via an increase in the Ca2+ efflux.
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The transient increase in I-l,4,5-P3 therefore seems to be the signal for the equally 
transient increase in Ca2+. Both return to basal or near-basal levels while the 
stimulus, and the contraction, are sustained. Rapid metabolism of I-l,4,5-P3 is 
accompanied by Ca2+ reuptake into the endoplasmic reticulum. Cytoplasmic I-1,4,5- 
P3 is reduced by a phosphatase, to produce inositol bisphosphate (I-l,4-P2), or by 
phosphorylation to the tetraphosphate I-l,3,4,5-P4 (Batty, 1985; Heslop et al., 1985; 
Irvine et al., 1986), which recent reports have indicated may have a role in regulating 
entry of Ca2+ across the plasma membrane (Irvine & Moor, 1986), followed by 
dephosphorylation to an inactive triphosphate, I-l,3,4-P3, which is unable to release 
Ca2+ from stores (Downes et al., 1986, Rossier et al., 1986).
The mechanism by which Ca2+ entry is subsequently stimulated is still unknown. It 
has been suggested that I-l,4,5-P3 acts on the plasma membrane to increase calcium 
permeability much as it does on the endoplasmic reticulum membrane, but evidence is 
conflicting on the subject (Slack et al., 1986; Kuno & Gardner, 1987; Streb et al.,
1984). An attractive hypothesis is that of the capacitive model of Ca2+ entry 
(Putney, 1986). Briefly, it is suggested that emptying of the intracellular calcium pool 
by I-l,4,5-P3 may secondarily open a pathway from the extracellular space into the 
pool and subsequently into the cytosol. Irvine and Moor (1986) further suggested that 
I-l,3,4,5-P4 is also involved in this process, that the release of Ca2+ by I-l,4,5-P3 is 
a necessary prerequisite, and that the two compounds are together necessary for Ca2+ 
entry.
4.3 Diacyl glycerol
The second messenger DAG is lipid soluble, remains in the membrane and activates 
PKC. Only 1,2-sn-DAGs are effective activators of PKC and the DAG is mainly of 
the l-stearoyl-2-arachidonyl-sn-glycerol variety (Nomura et al., 1986). The increase 
in DAG may be as transient as that of I-l,4,5-P3 as it is rapidly degraded to
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arachidonate and subsequent eicosanoid products or rejoins the phosphatidyl inositol 
cycle via conversion to phosphatidic acid by an ATP-dependent phosphorylation. 
Phosphatidic acid reacts with cytidine triphosphate (CTP) to yield CTP-DAG which 
interacts with myo-inositol to form phosphatidylinositol (Esko & Raetz, 1983) which 
is then transferred from the endoplasmic reticulum to the plasma, and other, 
membranes.
Sn- 1,2-DAGs stereospecifically activate PKC (Takai et al., 1979; Kishimoto et al., 
1980; Rando & Young, 1984), the 3-OH group and 1,2-carbonyls are required for 
activation (Cabot & Jaken, 1984; Ganong et al., 1986). The long chain fatty acid is 
required for at least one (either) of the 1,2 positions (Mori et al., 1982) with activity 
increasing from 3-11 carbons (Hannun et al., 1986a). Abdel-Latif (1986) concluded 
that the acyl ester must satisfy certain physical properties (i.e. water and lipid 
solubility) such that it partitions correctly into the membrane bilayer and obtains 
proper access to PKC.
The complex lipid mixture alters the enzyme conformation and DAG increases the 
affinity of PKC for phospholipid 2-3 fold while the calcum sensitivity is increased 
1000-fold to micromolar levels. (Kishimoto et al., 1980; Wise et al., 1982; Hannun 
et al., 1986a; Rasmussen & Barratt, 1984; Castagna et al., 1982). In the absence of 
DAG, lOOpM Ca2+ is needed for enzyme activation (Kikkawa et al., 1986). 
Conversely both phospholipid and Ca2+ increase the affinity of the enzyme for DAG 
(Hannun et al., 1986a). Kinetic studies indicate that one molecule of DAG activates 
one molecule of PKC in the presence of 4-10 phosphatidyl serine (Abdel-Latif, 1986; 
Nishizuka, 1984) and a model has been proposed in which a "primed" (PKC)! 
(phospholipid)4(Ca2+)1 complex is formed to which one molecule of DAG binds to 
activate the enzyme (Bell, 1986).
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DAG can also be generated from phosphatidic acid. Hydrolysis of 
phosphatidylcholine by phospholipase D generates phosphatidic acid as its lipid 
product, which is then converted to DAG by the action of phosphatidate 
phosphohydrolase (Peleck & Vance, 1989). Phospholipase D activity does not appear 
to be desensitised in the same rapid manner as phospholipase C and may therefore 
result in sustained production of DAG (Cook & Wakelam, 1989; Cook et al., 1990).
The duration of an increase in the DAG content of the plasma membrane, and thus of 
PKC activation, may therefore vary widely. Mellgren (1987) demonstrated that 
sustained association of PKC with the plasma membrane results in its proteolytic 
cleavage by calcium-dependent proteases (termed calpains by Murachi et al., 1981), 
to a 50kDa subunit, PKM, which has been implicated in mitogenesis (Murray et al., 
1987). This process in speeded up in the presence of DAG and Ca2+.
PKC can also be activated by arachidonic acid (Nishizuka, 1986). Thus, stimulation 
of phospholipase A2  can result in an increase in PKC activity and involvement of the 
inositol phospholipid signalling system is not essential for DAG generation or for 
PKC activation. Phospholipase A2  has a lower affinity for Ca2+ than does 
phospholipase C (Billah et al., 1980) suggesting that arachidonic acid production by 
this pathway may be stimulated by agonist-evoked increases in intracellular calcium. 
PKC is also known to regulate phospholipase A2  activity, thus these interactions 
allow for the subtle variation in the effects of different mediators according to the 
enzymes to which their receptors couple.
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4.4 Protein kinase C
PKC is a calcium and phospholipid dependent protein kinase of molecular weight 
77,000 Da. First identified in 1977 as an undefined protein kinase present in many 
tissues, it was found to be activated by limited hydrolysis with calpain (Takai et al., 
1977; Inoue et al., 1977). Cleavage results in the release of a catalytically fully active 
fragment which is rapidly removed from the cell. Later it was shown that in the 
absence of proteolysis it has activity that is dependent on Ca2+ and phospholipid, and 
enhanced by DAG (Takai et al., 1979; Kishimoto et al., 1980; Kuo et al., 1980). 
PKC is widely distributed in nature. In mammals the highest levels are found in 
platelets, spleen, vas deferens and brain, and the lowest levels in heart, adipose tissue 
and skeletal muscle (Kuo et al., 1980; Girard et al., 1986; Kikkawa et al., 1982). The 
subcellular location of PKC is hormonally regulated (see below) and varies with the 
tissue (Kuo et al., 1980; Girard et al., 1986; Kikkawa et al., 1982).
Structure
The enzyme is a single polypeptide chain composed of two domains. The 
hydrophobic domain interacts with calcium and phospholipid, binds to the 
membrane, and plays a regulatory role keeping the catalytic part inactive. The catalytic 
centre is located in the hydrophilic domain and is activated when DAG (or phorbol 
ester) binds to the regulatory domain (Ruegg & Burgess, 1989; Nishizuka, 1984; 
Abdel-latif, 1986). The ATP binding site and much of the rest of the catalytic portion 
shows a large degree of homology with other protein kinases (Ruegg & Burgess, 
1989).
The PKC family is comprised of several subspecies of PKC which respond 
differently to phospholipid, DAG and Ca2+ but which share a common basic 
structure. In brain tissue at least seven subspecies can be distinguished, one of which
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(the y-subspecies) is expressed only in central nervous tissue (reviewed: Kikkawa et 
al., 1989). Subspecies may be differently located in different cell types and many cell 
types contain several subspecies in variable ratios. The subspecies show subtle 
differences in their mode of activation, sensitivity to Ca2+, and catalytic activity 
(Rana & Hokin, 1990). Following cell stimulation, the subspecies may be down- 
regulated at different rates and may therefore have distinct roles in the regulation of a 
variety of physiological and pathological cellular responses. It is possible that 
different subspecies of PKC may be activated by different phospholipid metabolites 
(e.g. DAG, arachidonic acid or lipoxin A) that are produced in successive phases of 
the cellular response to surface receptor occupation (Nishizuka, 1988).
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Schematic structure of protein kinase C peptide chain, (from Kikkawa et al.. 1989)
Genes for the a, pi, p i l a n d y  subspecies have been identified on different 
chromosomes (Coussens et al., 1986) and 8, e and C subspecies have also now been 
found (Ono et al., 1987 & 1988). The subspecies thus far cloned have the same 
primary structure, shown schematically above, of a single polypeptide chain 
consisting of four conserved (C1-C4) and five variable (VI-V5) regions, however the 
8, e and £ subspecies lack the second conserved region (C2). In the diagram C, G, K,
\ C00M
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X and M represent cysteine, glyceine, lysine, any amino acid and metal respectively. 
The carboxyl terminal appears to include the catalytic domain. It contains the ATP 
binding site and shows significant sequence homology with other protein kinases 
(Ono et al., 1986; Parker et al., 1986).
The conserved region of the regulatory domain of PKC contains an amino acid 
sequence, between residues 19 and 36, that resembles a substrate phosphorylation 
site in its distribution of basic residues necessary for substrate recognition (House & 
Kemp, 1987). This area, termed a pseudosubstrate structure, may be responsible for 
maintaining the enzyme in an inactive form in the absence of activators such as 
phospholipids. The corresponding synthetic peptide acts as a potent and specific 
substrate antagonist, inhibiting both autophosphorylation and substrate 
phosphorylation in a competitive manner (House & Kemp, 1987). The peptide was 
uncompetitive at varying ATP concentrations, however, indicating that inhibition was 
not at the ATP binding site. Substitution of one amino acid, serine for alanine, 
transformed the synthetic peptide into a potent agonist.
The results suggest that the pseudosubstrate region binds to the active site of PKC 
and inhibits its activity. Activation of the enzyme by phospholipids could cause a 
conformational change that removes the pseudosubstrate sequence from the active site 
and therefore allows access to protein substrates.
Activation
In the non-activated cell PKC exists in the cytosol as an inactive soluble enzyme and 
has a low sensitivity to calcium (Kikkawa et al., 1982). When the DAG concentration 
of the plasma membrane increases following PI hydrolysis, the enzyme is 
translocated to the plasma membrane where it binds to the inner surface and 
associates with the proper mix of phospholipids to become active (Nishizuka, 1986).
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While PKC can be activated by the synergistic action of increased intracellular 
calcium concentrations and increased formation of DAG (detailed above), it can also 
be activated by limited proteolysis with calpain and is most suceptible to this in its 
membrane-bound state (Nishizuka, 1986).
Although PKC generally remains active for only a short time, the consequences of 
PKC activation may persist considerably longer depending on the stability (resistance 
to proteases) of the phosphate covalently attached to the substrate molecule 
(Nishizuka, 1986). Numerous substrate proteins for PKC have been discovered in 
vitro (see below).
There is a large body of evidence suggesting that PKC has a dual action, exerting 
positive as well as negative control over various steps of the cell signalling process 
(Reviewed: Nishizuka, 1986 & 1988; Kikkawa & Nishizuka, 1986). However, most 
of the published data to date suggests that activation of PKC does not result in 
exaggerated responses to receptor-mediated events. In the early stages of cell 
responses PKC is thought to act synergistically with Ca2+ as part of a positive 
forward response. Subsequently it frequently acts as a negative feedback control, for 
example PKC is implicated in the down regulation of some receptors which occurs 
after agonist stimulation (Nishizuka, 1986). Receptors that are phosphorylated by 
PKC include those for muscarinic and p-adrenoceptor agonists and endothelial 
growth factor (Safran et al, 1987; Sibley et al, 1986; Davis & Czech, 1986; Friedman 
et al, 1984; Iwashita & Fox, 1984). Phosphorylation is thought to reduce the affinity 
of the receptor for the agonist, or to interfere with agonist binding by initiating 
internalisation of the receptor. However, in aortic smooth muscle cells, activation of 
PKC inhibited phosphatidylinositol responses to angiotensin II but did not alter 
receptor affinity or numbers (Katada et al, 1985), suggesting that intracellular 
coupling may be altered, perhaps due to phosphorylation of the receptor linked G 
protein(s). Activation of PKC by PMA can inhibit PIP2 hydrolysis in response to
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muscarinic receptor occupation without altering the binding properties of the receptor 
(Orellana et al., 1985; Itoh et al., 1988).
PKC is implicated in control of secretion & exocytosis, smooth muscle contraction, 
DNA synthesis, gene expression and cell proliferation (Nishizuka, 1986 & 1988; 
Kaibuchi et al., 1986; Kikkawa & Nishizuka, 1986). In all of these processes 
activated PKC acts in synergism with the increased intracellular calcium 
concentration. However, in some processes an additional pathway is involved in 
eliciting full activation: for example for rapid cell proliferation, some growth factor, 
even in low concentration, is needed.
Other lines of evidence suggest that PKC modulates ion conductance by 
phosphorylation of membrane proteins such as channels, pumps, and ion exchange 
mechanisms. In various cell types PKC stimulates Ca2+ extrusion by activating the 
Ca2+-transport ATPase and the Na+/Ca2+ exchange protein (reviewed: Nishizuka, 
1986 & 1988).
Clearly many signals focus on PKC and this enzyme, in turn, plays a central role in 
the regulation of a wide variety of cellular processes, from calcium signalling to the 
contraction of the smooth muscle itself. An alteration in the pattern or extent of PKC 
activation could, therefore, be a factor in the hyperreactive airways of the type found 
in asthmatics.
4.5 Chemicals influencing PKC directly.
PKC can be artificially activated by several substances. Activators of PKC include the 
phorbol esters (Castagna et al., 1982; Fig. 4.4), the membrane soluble analogues of 
DAG: oleoylacetyl glycerol (OAG) and dioctanoyl glycerol (DOG), and several other
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Schematic diagram of the general molecular structure A) of phorbol esters (Anwyl, 
1989) and B) of diacylglycerol (Nishizuka 198x). R' and R" are ester side chains of 
varying length.
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classes of compound. The phorbol esters are the most potent of the PKC activating 
drugs and consequently the most useful experimentally (Epand & Lester, 1990). 
Several phorbol esters have been used in the investigation of the properties of PKC, 
including the weak promotor 12-deoxyphorbol 13-isobutyrate (DPB), phorbol 12,13- 
didecanoate (PDD) and the photoaffinity probe phorbol 12-p-azidobenzoate 13- 
benzoate (PaBB; Declos & Blumberg, 1983). However, the esters most frequently 
employed are phorbol 12-myristate 13-acetate (PMA) and phorbol 12,13-dibutyrate 
(PDBu) which each have an active, 4p, and an inactive, 4a, isomer. Nomenclature 
confusion arises due to the use, by some authors, of the name 12-0- 
tetradecanoylphorbol 13-acetate (TPA) which is the same compound as PMA.
PDBu has been used in studies to demonstrate specific, saturatable binding in cells 
{section 4.6) as the use of the more lipophillic PMA results in a high degree of non­
specific binding. However, PMA is the most potent of the phorbol esters and has a 
higher binding affinity than PDBu in all the systems studied. Thus, although PDBu is 
used as the ligand of convenience for measuring binding, the receptor being measured 
is more properly considered as a PMA receptor (Blumberg et al., 1983).
Phorbol esters.
Phorbol esters are a class of plant toxins produced by the Euphorbias and are widely 
known as tumour promotors, agents which are not themselves carcinogenic but 
which induce tumours in animals exposed to a subthreshold dose of carcinogen. 
Rohrscheider & Boutwell (1973) suggested they might act by binding to some 
physiological receptor, but as recently as 1981 the site of their action was still 
unknown. With the discovery of PKC by Nishizuka and coworkers (Inoue et al., 
1977; Takai et al., 1977), and the interest this protein kinase aroused, it became 
apparent that the distribution of the phorbol ester binding activity and of the enzyme 
were generally very similar. Castagna and coworkers (1982) demonstrated that the
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dose response curve for PMA activiation of PKC was very similar to the saturation 
curve for PMA binding to its receptor and subsequent investigations by the same 
group confirmed this to be the case (Sano et al., 1983; Yamanishi et al., 1983).
The use of a radioactively labelled phorbol ester [3H]PDBu revealed high affinity 
binding sites in a wide range of species and tissue preparations. Phorbol ester 
receptors were present not only in the various vertebrate systems examined but also in 
nematodes, sea-urchins and fruit flies (Blumberg et al., 1983). Highest levels of 
binding were seen in brain tissue where the absolute value, 30pmol/mg protein, was 
much greater than that for neurotransmitter receptors (<2pmol/mg; Blumberg et al., 
1983).
Phorbol esters bind to the particulate fraction of cells in a specific, saturatable and 
reversible manner (Dreidger & Blumberg, 1980) which can be competitively inhibited 
by diolein, a derivative of DAG (Blumberg et al., 1984). The highly lipophilic 
phorbol esters intercalate with the membrane and mimic the actions of DAG by acting 
at the same site on the enzyme to activate protein kinase C both in vitro and in vivo. 
(Castagna et al., 1982; Yamanishi et al., 1983). Interaction with phorbol esters is 
regulated by calcium and phospholipid and occurs at the same site as DAG (Kikkawa 
et al., 1983; Hannun & Bell, 1986). Indeed DAG competitively inhibits phorbol ester 
binding to a brain cytosolic phorbol ester aporeceptor (Sharkey et al., 1984). Phorbol 
esters substitute for DAG at very low concentrations (1000-fold lower than DAG) 
both in vitro and in vivo (Nishizuka, 1984). However PMA is hardly degraded and 
may therefore distort the normal sequence of phosphorylation events.
Although a degree of heterogeneity in phorbol ester binding was seen in certain 
tissues (Blumberg et al., 1984), and despite the fact that phorbol esters are known to 
have effects that are not mediated by protein kinase C (section 4.6), this enzyme is 
generally accepted as the principal site of action of the phorbol esters (Yamanishi et
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al., 1983; Baraban et al., 1985; Forder et al., 1985). Copurification of kinase 
activity and phorbol ester binding (Ashendel et al., 1983; Kikkawa et al., 1983; 
Neidel et al., 1983) confirmed that PKC is a major phorbol ester receptor in cells. 
The basis for the phorbol receptor heterogeneity could be multiple genes, arising from 
gene duplication and divergence, that code for receptor variants (section 4.1).
Frezard et al. (1989) monitored the interaction of PMA with phosphatidyl serine- 
containing unilamellar vesicles using circular dichroism (CD) and observed changes 
in the CD spectra of PMA upon binding. They assigned these to the embedding of 
the phorbol ester in the membrane layers and calculated that only 2-5% of the amount 
of phorbol ester added was embedded after 1 minute incubation. This results suggests 
that either phorbol esters entering the membrane is not necessary for the activation of 
PKC or that the amount of phorbol ester needed is very small. The latter is likely as a 
1:1 ratio of PMA (or DAG) to PKC is reported (section 4.3).
Several reports (Ballester & Rosen, 1985; Blackshear, 1985; Hepler et al., 1988) 
indicate that PMA elicits the translocation of the enzyme from the soluble fraction to 
the membrane and its subsequent depletion, termed down-regulation. Indeed Neidel 
and Blackshear (1986) cite papers covering 11 cell types in which phorbol esters have 
been shown to cause translocation. Kuo (1986) reports that after 30 minutes 
incubation with 200nM PMA all measurable PKC was bound to the plasma 
membrane while after 2 hours no PKC staining was found, presumably because the 
enzyme had been degraded or freshly secreted by the cell. Such a situation could 
result in desensitization to agonist stimulation.
The effects of PKC activation by phorbol esters have been studied in a variety of 
tissue preparations. However most of the studies undertaken on the action of phorbol 
esters in smooth muscle have utilised mammalian vascular tissue, in which they are 
reported to induce a progressive contraction that is slow in onset (Danthuluri & Deth,
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1984; Forder et al., 1985; Spedding, 1987). The effect of phorbol ester-induced 
PKC activation on the response to calcium mobilizing agonists is less clear-cut. They 
have been shown to inhibit al-adrenoceptor-mediated responses and the associated 
release of I-l,4,5-P3 (Danthuluri & Deth, 1984; Carmelo et al., 1988), to increase or 
decrease the amplitude of contraction to ACh (Itoh et al., 1988) and to inhibit or 
enhance calcium-induced contractions (Baraban et al., 1985).
The limited amount of work carried out on airway smooth muscle is similarly 
inconclusive. Despite the central role played by PKC in smooth muscle excitation- 
contraction coupling, relatively little work has been done on the effects of phorbol 
esters in airways and the reported responses have been variable. Park and Rasmussen 
(1985) found that PMA itself had no effect on bovine trachea, but when added with 
the calcium ionophore A23187 the resulting response was similar to that produced by 
the muscarinic agonist carbachol and could be potentiated by BAY-K8644. Souhrada 
& Souhrada (1989a) reported a triphasic contractile response to PMA in guinea pig 
trachea while Schramm & Grunstein (1989) saw a concentration dependent effect in 
rabbit trachea, high concentrations of PMA producing a relaxation of methacholine- 
induced tone and lower concentrations producing a contraction.
4.6 PKC-independent effects o f phorbol esters
Phorbol esters have been shown to exert effects that are independent of PKC. For 
example both PDBu and its 4a-isomer depressed whole cell barium current through 
calcium channels in hippocampal neurons (Doemer et al., 1990). PDBu exerted its 
effect via the activation of PKC, which could be blocked by H7. However the 4a- 
isomer is ineffective at activating PKC yet still exerted a (100-fold weaker) effect on 
the barium current. 4a-PDBu was only effective on the outside of the cell, suggesting 
it had its effects via an extracellular binding site or that its orientation in the membrane
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was crucial to its effects on calcium channels. PKC-independent effects began to 
appear in the range of 5-10fiM.
Maleci and coworkers (1990) showed that PMA pre-treatment of a glioma cell line 
(SNB-19) made them less susceptible to lymphokine-activated killer cell-mediated 
lysis. This effect was produced by low concentrations of PMA, was reversible, and 
was not blocked by PKC-inhibitors. PMA may have exerted its effects by a PKC- 
independent mechanism, or these glioma cells may possess an isozyme of PKC 
which is insensitive to the inhibitors employed.
At high concentrations (50|iM) phorbol esters and analogues of DAG are thought to 
have non-specific effects. At this concentration PMA and OAG have been shown to 
produce a significant release of serotonin from platelets in the absence of a significant 
increase in [Ca2+]. These release reactions are possibly due to the compounds acting 
as membrane perturbers or fusigens or stimulating superoxide production (Kaibuchi 
et al., 1983; Yamanishi et al., 1983; Witz et al., 1980).
Section 5
METHODS
5.1 Introduction to methods section: In vitro study o f airway smooth 
muscle.
Overview
Although most modem in vitro studies of airway smooth muscle function make use 
of organ bath techniques, early qualitative studies were performed on the isolated 
trachea or whole bronchial tree. Thin slices of lung from the gelatine-filled bronchial 
tree were examined with a microscope during the addition of drugs (Sollman & 
Gilbert, 1937) while isolated tracheal tube preparations were used in pharmacological 
and physiological studies (Carlyle, 1964; Hakansson & Toremalm, 1967).
Quantitative studies have provided more detailed information. The direct measurement 
of airway smooth muscle contraction or relaxation in response to an agonist is 
possible with the use of organ baths coupled with force transducers and recorders. 
Castillo and DeBeer, Akcasu and Patterson did much of the early work on tracheal 
smooth muscle. Castillo and DeBeer (1947) sectioned guinea-pig trachea into 12 
rings which were tied together with the smooth muscle in alignment, kept under 
tension by the natural tendency of the cartilage to spring open. This method was 
subsequently adapted by Akcasu, first in 1952, when to obtain greater sensitivity, he 
opened up the rings by cutting through the cartilage and later in 1959, when he cut 
away most of the cartilage and tied the remaining cartilagenous ends together. The 
technique was further modified by Foster (1960) who, in order to minimise the 
interanimal variation, connected the odd numbered (open) rings from one animal with 
the even numbered ones from a second.
Rosa & MacDowell (1951) and Patterson (1958) developed a bronchial preparation 
that involved less manipulation of the tissue. They found that bronchi cut into a single 
spiral was more sensitive than the chain of connected rings, provided a spiral of
sufficient length could be obtained. This method was rediscovered by Constantine 
(1965) and is still used. (Fleisch et al, 1970; Brink et al, 1980).
The subsequent development of techniques utilizing single tracheal (Danko et al., 
1968) and bronchial (Stephens et al., 1968) rings allowed the preparation of several 
tissue rings from a single piece of tracheal or bronchial tissue. Tension is usually 
recorded isometrically and the ring preparations used for physiological and 
pharmacological studies; the effects of several drugs or conditions could be tested in 
paired rings taken from the same animal. Second or third generation airways (about 
1mm diameter) can be studied this way, by the simple modification of using two 30- 
gauge disposable needles bent into shape to mount the tissue rings (Hooker et al., 
1977).
In order to investigate the properties of smooth muscle of very small airways, use has 
been made of tissue strips. Strips of lung parenchyma have been used to record 
tension changes or mediator release from the most peripheral parts of the lung 
(Kapanci et al., 1974; Lulich et al., 1976; Drazen & Schneider, 1978). This method 
has been criticised however, as the preparation may be heavily contaminated with 
other types of cells, eg. vascular smooth muscle cells, which could contribute to any 
response produced (Finney et al., 1984, 1985). Other groups have developed 
techniques using tracheal or bronchial muscle strips, dissected free of connective 
tissue and cartilage, indeed as long ago as 1912 Trendelenburg experimented on 
strips of muscle and mucosa taken from the bronchi of calves and pigs and cleaned of 
cartilage. Trachealis muscle is considered to be the purest muscle preparation of the 
bronchial tree (approximately 75% muscle; Stephens et al., 1969). This technique has 
been considerably refined and has been used in a variety of electrophysiological and 
pharmacological experiments (Offermeier & Ariens, 1966; Cobum & Tomita, 1973, 
Richardson & Bouchard, 1975).
Choice of preparation
In asthma both the central and the peripheral airways are thought to be involved in the 
bronchoconstrictor response. However, most work has been undertaken on the 
smooth muscle of the trachea and large bronchi. With the objectives raised against the 
use of the parenchymal strip preparation, the single bronchial ring provided the best 
available means of measuring small airway responses and was therefore utilized in 
this studyt.  Several of the groups working in airway smooth muscle 
physiology/pharmacology at present utilize closed or opened bronchial rings (Minette 
& Barnes, 1988; Roberts et al., 1984/1985) with the result that a bank of literature is 
available for consultation.
tR e c e n t developm ents in m yography, utilizing devices designed to m onitor tone in sm all resistance 
b lood vessels o f  dow n to  80fiM  d iam eter (M ulvany et al., 1990), m ay perm it even m ore accurate 
m easurem ent o f  sm all airw ay responses. This technique has not yet been applied to bronchioles but 
should allow  d irect m easurem ent o f  the responses o f  airw ays in the periphery o f  the lung to be made.
5.3 Methods - The rabbit preparation
Adult New Zealand White rabbits of either sex, weighing 2.5-3.5 kg were killed by a 
blow to the cervical spine. Secondary bronchi were isolated from the lungs, cleaned 
of loose connective tissue and placed in well oxygenated Krebs Henseleit (Krebs) 
solution.
The Dissection
An incision was made at the base of the rib cage and the sternum cut up the midline 
for its full length. Lateral cuts were made at the top and bottom of the incision on 
either side, allowing the rib cage to be opened up to reveal the thoracic viscera.
The conical thoracic cavity contains the thymus gland, heart and lungs (Fig. 5.1). The 
thymus resembles a large mass of fatty tissue and, especially in younger rabbits, may 
almost cover the heart. Beneath the heart and thymus lie the right and left lungs, the 
right having four lobes while the left has only two.
The main thoracic blood vessels, the aorta and vena cava, are closely associated with 
the lungs. From the heart the aorta curves leftwards then dorsally to run under the 
lungs on the dorsal wall of the thoracic cavity. The posterior vena cava approaches 
the heart from its opening in the diaphragm (over and between the lungs), and is 
accommodated in a deep groove in the ventral surface of the right lung. Figure 5.2 
shows the relative positions of the different vessels in a transverse section of the 
thoracic cavity passing through the lower portion of the heart.
While it is possible, with care, to remove the lungs without damaging the heart and 
vasculature, the simplest and fastest technique, and that used here, is to cut through 
the cervical portion of the trachea, oesophagus and blood vessels. The trachea can
Figure 5.1 (from Whitehouse & Grove, 1967)
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then be raised up with forceps and the connective tissue carefully cut away enabling 
the entire heart and lungs to be lifted free and cleaned up outside the thoracic cavity.
The walls of the rabbit airway contain a substantial amount of cartilage in the trachea, 
primary and secondary bronchi whereas those of the third order bronchi contain only 
fragments of cartilage (Fujiwara, 1988). In these studies rings of second order 
bronchi were prepared from airway immediately above the bifurcation to third order 
bronchi, where there was relatively little cartilage. When the airways were sufficiently 
large rings of third order bronchi were utilized.
Bronchi were isolated by blunt dissection and the loose connective tissue gently 
removed with fine forceps. Care was taken to avoid handling the epithelial surface of 
the airway.
5.4 Methods - Human tissue
Human bronchial smooth muscle samples were obtained from the thoracic surgical 
units at the Western Infirmary, Glasgow and Hairmyres Hospital, East Kilbride. 
Samples of second to sixth order bronchi were obtained from patients undergoing 
surgery for bronchial carcinoma. Immediately after surgical resection specimens of 
macroscopically normal tissue were provided be the pathologist and transported to the 
lab in Krebs fully saturated with 5% CO2  in O2 . Bronchi were dissected free of loose 
connective tissue and washed in fresh Krebs to remove any blood. Bronchial rings 
were cut into 3-4mm sections and used immediately or stored overnight at 4°C in 
well-oxygenated Krebs. This procedure has been shown to have no significant effect 
on the response of the tissue to contractile or relaxant agonists (Brink, 1980; De 
Jongst et al., 1985).
Results in human tissue are obviously the most interesting and clinically relevant for 
the study of processes related to asthma. Unfortunately the tissue is in short supply 
and varies widely in quantity and condition. As the tissue is obtained at thoracotomy 
the supply is irregular and suitable specimens are therefore precious. Thus, all initial 
experiments were done in the rabbit airway preparation and this tissue was 
subsequently used to tease out the mechanism once the important positive result was 
obtained in human airway.
Notes on the human tissue:
Although the lung tissue was macroscopically normal most of the donors had 
pulmonary carcinoma and most would have been cigarette smokers. In vivo 
responsiveness to histamine is increased in patients who are heavy smokers (Roberts 
et al., 1985). Although differences in responsiveness might therefore be expected 
between lung tissue from diseased and healthy patients, several studies have been 
unable to find a relationship between in vivo hyperresponsiveness and in vitro airway 
reactivity (Vincenc et al., 1983; Roberts et al., 1984, 1985). It is unlikely that the 
responses obtained from these specimens would differ significantly from those from 
pulmonary disease-free tissue.
Recent work suggests that neutrophil products may increase the reactivity of 
bronchial smooth muscle (Hallahan et al., 1990). Phorbol esters are known to 
activate a variety of inflammatory cells and to stimulate release of pre-formed 
mediators which could produce modulation of bronchial smooth muscle contractility. 
In an attempt to remove all inflammatory cells from the preparation tissues were 
washed frequently in fresh Krebs. Nevertheless, it is likely that some cells remained 
in the specimen. While mediator release may play a role in the response of the smooth 
muscle to PMA and cannot be discounted, previous studies in airway tissue found no 
significant effect of activated inflammatory cells on acetylcholine responsiveness in 
vitro (McAlpine et al., 1989).
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5.5 Setting up
Bronchi (3-5mm diameter) were cut into rings of approximately 3mm length and 
suspended between two wire hooks in 5ml water baths. The lower support was 
attached to a modified tissue holder and the upper hook attached by a cotton thread to 
an isometric transducer (Fig.5.3). The Krebs was aerated with a carbogen mixture 
(5%C02 in 02) and maintained at 372C. Tissue rings were placed under lg  tension 
and allowed to equilibrate in the bath for lhr, during which time they were washed 
with fresh Krebs every 15 minutes. By 60 minutes all tissues had reached a stable 
tension that was unaltered by further washing. If necessary (if a tissue had relaxed to 
less than 0.5g) tissues were retensioned and allowed to recover till they remained at a 
steady tension of between 0.5 and 1.0 grams. Changes in tension were measured on 
Grass isometric (FT03) force displacement transducers and recorded on a Linseis 
(L2005 series) strip chart recorder.
5.6 Electrical field  stimulation studies
The modified tissue holders included two platinum wire electrodes which were 
connected to a Square One electrical stimulator. Tissue rings underwent electrical field 
stimulation with various parameters. A 10 second train of 0.1msec pulses at a 
supramaximal voltage of 50V was applied at frequencies from 0.5-100Hz in order to 
construct a frequency response curve. In subsequent experiments rings were 
stimulated at 4, 16 or 30Hz which represent approximately 25, 65 & 90% of the 
maximal response to EFS. Stimulation was repeated at 5 minute intervals until 3 
successive contractile responses were within 10%. The average of these 3 responses 
was designated 1 0 0 % and all subsequent responses expressed as a percentage.
Following addition of PMA, stimulation continued every 5 minutes for an hour, with 
further stimulation at 75 and 90 minutes. In order to assess the cholinergic nature of
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the response and the importance of calcium entry to the potentiation by PMA, parallel 
experiments were run in which the tissues were incubated with atropine or verapamil 
for 20 minutes prior to addition of the PMA. In all experiments paired untreated 
tissue rings served as time controls.
5.7 Cumulative concentration response studies
This type of protocol provides an extensive pharmacological analysis; from the 
response curve one can calculate the Tmax, EC5 0  & pD2  values (see data analysis) 
which allow comparison of the sensitivity and maximum contractile response of the 
tissues.
Cumulative concentration response curves (CCRCs) were obtained in each tissue by 
increasing, by 3-fold increments, the organ bath concentration from InM to 30pM 
ACh. The threshold concentration of contraction to ACh in rabbit secondary bronchial 
smooth muscle was 0.03-0. lpM .
On reaching and maintaining a contraction to the maximum concentration used, the 
tissues were washed till they regained resting tone. Following full recovery the 
tissues were incubated with lpM  or lOfiM PMA for a period of 45min at which point 
a second CCRC was completed in the presence of the phorbol ester. In all 
experiments time controls were included to assess the effect of time alone on the 
sensitivity of the preparation to ACh.
5.8 Submaximal dose studies
This type of protocol is more accurate than the CCRC study described above when 
less than log order changes in sensitivity are involved.
The tissues were contracted with a single sub-maximal concentration of lOpM ACh 
or histamine, equivalent to approximately 55% of contraction to 300|iM ACh and 
approximately 6 6 % of maximum contraction to histamine. On reaching a steady 
plateau the rings were rinsed three times in fresh Krebs and allowed to recover for 10 
or 30 minutes before readdition of 10pM ACh or histamine respectively. This 
protocol ensured recovery of the full contractile response and was repeated until 3  
successive responses differed by less than 10%. Their average value was designated 
100% and all subsequent responses were expressed as a percentage. The tissues were 
then incubated with 1 or lOpM PMA for 45min at which point 10pM ACh or 
histamine was again administered. Following washout and recovery a further two 
contractile responses to 10|uM ACh or histamine were obtained.
In experiments using antagonists, these drugs were added to the organ bath 30 
minutes before the addition of the PMA. In all experiments a time control was 
included to examine the effect of time alone on the response of the tissue to ACh.
5.9 Antagonist studies
In order to determine the contribution of Ca2+ influx, Na+-H+ exchange and cyclo- 
oxygenase products to the effects of PMA in the submaximal dose studies, parallel 
series of experiments were run in which the tissues were incubated with verapamil 
(10pM), nifedipine (3pM), amiloride (lOOfiM) or indomethacin (lOfiM) 30min prior 
to the administration of PMA. The effects of the putative PKC inhibitors H7 (10|iM) 
and staurosporine (0.5fiM) were also examined.
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5.10 Solutions and Drugs.
The following drugs were used in this study: acetylcholine chloride, amiloride
hydrochloride, atropine sulphate, histamine diphosphate, indomethacin, l- ( 5 - 
isoquinolinylsulphonyl)-2-methylpiperazine (H7), nifedipine, phorbol 12-myristate 
13-acetate (PMA), staurosporine, verapamil hydrochloride (all Sigma Chemical Co.).
PMA was prepared as a 0.01M stock solution in dimethyl sulfoxide and diluted with 
distilled water to give final bath concentrations of 0.001 to lOOfiM. Indomethacin, 
nifedipine and BAY-K were dissolved in a minimal quantity of alcohol then diluted 
with distilled water. Staurosporine was disolved in a solution of distilled water and 
95% ethanol (1:1 ratio). All other compounds were made up in distilled water.
Composition o f Krebs-Henseleit solution (millimoles per litre):
NaCl 118.4, N aH C 0 3  25.0, KC1 4.7, KH2 P 0 4  1.2, M gS0 4  1 .2 , CaCl2  2.5 & 
Glucose 11.0.
NB. In preparation of the nominally calcium-free Krebs 2.5mM CaCl2  was omitted 
from the solution.
5.11 Data analysis
Data were expressed as mean ± standard error of the mean (s.e.m.) and statistical 
significance was assessed by means of paired two-tailed Student's r-tests in which 
p<0.05 was considered significant. In antagonist experiments the need for multiple 
comparisons negated the use of Student's r-tests and statistical significance was 
therefore assessed using analysis of variance (ANOVA) at 95% significance level.
In all first CCRC, the contractile response to each concentration of ACh was 
expressed as a percentage of the maximal response (Tmax) obtained to ACh in that 
tissue. Responses to each concentration of ACh in the second CCRC were also 
expressed as a percentage of the Tmax obtained for the first curve in that tissue. In 
each experiment the EC5 0  (the concentration of agonist producing 50% of the 
maximal response in that curve) was determined, and the corresponding pD 2  value 
(the negative log of the EC5 0 ) calculated. pD2  values were then compared using the 
paired Student's r-test.
Phorbol esters have previously been shown to contract smooth muscle (section 4.5). 
In this preparation contraction was frequently seen at 100pM PMA . Our experiments 
were carried out at subthreshold (<10|iM PMA) concentrations. Contractile 
responses did occasionally occur (< 1 0 % of tissues), but where any contraction 
amounted to more than 0.15g that data was omitted from the calculations. In a 
random sample of fifty tissues incubated with PMA, three (6 %) produced a rise in 
baseline tension and were excluded from the analysis, as were another four tissues 
(8 %) which developed spontaneous contractions on addition of PMA.
Section 6
RESULTS
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6.1 Electrical f ie ld  stimulation
While there is sympathetic, parasympathetic and NANC innervation of the lung 
(section 2.1), principal nervous control of the proximal bronchi is cholinergic. 
Electrical field stimulation of rabbit secondary bronchi produced an immediate rapid 
contraction. The response was biphasic; no relaxation was evident after the initial 
contraction and recovery. Contractions were elicited over a range of frequencies (0.5- 
100Hz) using the stimulation parameters: 50V, 0.1ms pulse width, 10s train, 
stimulating once every 5min. A graded increase in size of contraction was seen with 
increasing frequency (Fig. 6.1). Stimulation at 64 Hz produced the maximal response 
obtained in this preparation; subsequent contractions to 80 and 100Hz produced 98% 
and 90%, respectively, of the contractile response to 64Hz.
6.2 Effect o f  phorbol ester on responses to EFS
Addition of PMA to the tissue at time zero produced a slow steady increase in the 
contractile response to EFS which reached a plateau after 45-60 minutes. While it is 
not known at which frequencies the nerves are stimulated in vivo, the potentiation of 
response was seen across a range of frequencies. At 4, 16 & 30Hz, frequencies 
producing 24, 65 and 8 8 % of maximum contraction to EFS (approx. lg; Table 6.1), 
60 minutes incubation with PMA (10|iM) increased responses to stimulation to 
131(16)%, 134(6)% and 104(6)% respectively (Fig. 6.2), all of which were 
significantly greater than their time controls (n=5-9; p<0.05).
Although greatest potentiation by PMA (an increase of approximately 30%) was seen 
at the lower stimulation frequencies, contractile responses to 4Hz EFS were generally 
smaller and more variable than those obtained at 16Hz and consequently frequently 
failed to reach significance. Stimulation at 16Hz consistently produced responses of 
0.5-1.0 grams (approximately 50% of the maximum concentraction to ACh in this
preparation, 1.32±0.15g) and this frequency was employed in subsequent 
experiments.
The potentiation of the contractile response by PMA was concentration dependent. 
The contractile response to 16Hz EFS increased steadily over 45-60 minutes after the 
addition of 1-lOOjiM PMA whereas lower concentrations (0.001-0. l}iM PMA) failed 
to elicit any significant change. Time controls showed no increase over the same 
period (Fig. 6.3a).
At 60 minutes into incubation 1,10 & lOOpM PMA had produced a mean increase in 
stimulation-induced contraction from baseline values to 124(8), 178(27) and 
235(50)% respectively (Fig. 6.3b). These responses were significantly greater than 
the respective time control values of 77(9), 74(10) and 94(4)% (n=5-9; p<0.05).
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Figure 6.1
Effect of frequency on the response of rabbit secondary bronchi to EFS. 
Responses to 0.5-64Hz are expressed as A) as grams tension, or B) as a 
percentage of the maximum contraction elicited by 64Hz in each tissue.
Each bar represents the mean ± s.e.m. (n=5, x=14).
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Response of rabbit secondary bronchi to EFS at different frequencies.
Stimulation Tension Produced % Max response to EFS % Max response to ACh 
Frequency (grams) (64Hz) (300fiM)
4 Hz 0.27 (0.06) 24% 20%
16 Hz 0.63 (0.10) 65% 48%
30 Hz 0.83 (0.11) 8 8 % 63%
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Figure 6.2
Effect of incubation with PMA on the response of rabbit secondary bronchi to 
EFS. Results are shown at 60 minutes into the incubation period and are 
expressed as a percentage of the initial response to EFS. Open bars represent 
time control responses to 4, 16 & 30 Hz, hatched bars show the effect of lOfiM 
PMA. Each bar represents the mean ± s.e.m. (n=5-9). Statistically significant 
differences between responses in the absence and presence of PMA in paired 
tissues are represented by *p<0.05, **p<0.01, Student's f-test.
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Figure 6.3
Effect of concentration on the potentiation of response to EFS of rabbit 
secondary bronchi. Results are expressed as a percentage of the initial response 
to 16Hz EFS and show A) the effect of 0.001-100fiM PMA on the response to 
EFS over a 90 minute period, and B) the effect of l-100|iM  PMA at the plateau 
phase, 60 minutes into the incubation period. Open bars represent time control 
responses to EFS, hatched bars represent test responses in the presence of 
PMA.
Each point represents the mean ± s.e.m. (n=7-8). Statistically significant 
differences between responses in the absence and presence of PMA in paired 
tissues are represented by *p<0.05, **p<0.01, Student's f-test.
6.3 Effects o f antagonists on the potentiation o f EFS by PM A
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Atropine
Addition of 0.1 }iM atropine, a muscarinic antagonist, virtually abolished the response 
of the control tissues and also of the PMA-treated tissues to EFS at 16Hz. At 60 
minutes into incubation PMA had increased the response in test tissues to 250(60)% 
of its initial value (Fig. 6.4). This was significantly different from time control values 
which had decreased to 85(5)% (n=6 ; p<0.05). Atropine greatly decreased the control 
response to EFS which was reduced, by 60 minutes, to 5(4)% (p<0.001). PMA 
failed to potentiate responses in the presence of atropine (p>0.05); responses 
remained at only 8(3)% of their initial value (p<0.001).
Verapamil
Incubation with verapamil (10|iM) decreased the response of rabbit secondary 
bronchi to EFS (Fig. 6.4). Over the incubation period verapamil reduced the mean 
response to EFS to 48(6)%, while paired time controls showed no significant change 
in size at 91(6)%. PMA (10|iM) produced an increase in response to EFS to 
185(37)%. Pre-incubation with verapamil prevented the potentiation of response by 
PMA, at the 60minute time point responses to EFS in these tissues reached only 
45(11)% of their initial response (n=5,p>0.05).
H7
Incubation with H7 attenuated the PMA-induced potentiation of response to EFS. H7 
(lOjiM) itself significantly decreased the response from 0.82(0.l)g  to 0.55(0.l)g, a 
decrease of 3 3 (2 .9 )% (expressed as a percentage of the initial control response), 
while paired control tissues showed no significant change (n=12, p<0.05). Addition
of PMA (10|LlM) produced a significant increase in the response to EFS in both the 
control tissues and those pre-incubated with H7. 60 minutes incubation with PMA 
produced an increase of 37(8.3)% (n=5, p<0.05) in the control tissues and a 
significantly smaller increase of 15(2.6)% in H7-treated tissues. Even expressed as a 
percentage of the post-H7 response, the potentiation by PMA, at 17(4.1)%, was less 
than without H7 (Fig. 6.5).
Staurosporine
Incubation with staurosporine prevented the potentiation of response to EFS by 
PMA. Staurosporine (0.5 |iM) itself decreased the response of rabbit secondary 
bronchi to EFS (Fig. 6.5); over the incubation period the mean response was 
significantly reduced to 54(7.2)% (p<0.05; n=5). PMA (10|iM) produced a 
significant increase in response to EFS to 137(12.7)%, while paired time controls 
showed no change in size at 100(5.5)%. Pre-incubation with staurosporine prevented 
any potentiation of response by PMA, at the 60minute time point responses to EFS in 
these tissues reached only 50(17.4)% of their initial response (n=5,p>0.05).
Results of antagonist studies are summarised in tables 6.2 & 6.3, and in figure 6.6.
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Figure 6.4
Effect of atropine and verapamil on the PMA-induced potentiation of response to EFS 
in rabbit secondary bronchi. Open bars represent time control responses to 16Hz 
EFS. Second bars represent the response to EFS at 60 minutes into incubation with 
10|iM PMA. Third and fourth bars represent the effect of antagonist alone, A) 
atropine (O.lpM) or B) verapamil (10|lM), and the effect of antagonist + PMA 
respectively.
Responses are expressed as a percentage of the initial response obtained in each 
tissue. Each point represents the mean ± s.e.m. (n=5-6). Statistically significant 
differences between test responses and paired controls (*), between (antagonist + 
PMA) and PMA alone (f), and between (antagonist + PMA) and antagonist alone 
(#) were assessed by ANOVA, 95% confidence limits.
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Figure 6.5
Effect of H7 and staurosporine on the PMA-induced potentiation of response to EFS 
in rabbit secondary bronchi. Open bars represent time control responses to 16Hz 
EFS. Second bars represent the response to EFS at 60 minutes into incubation with 
IOjiM PMA. Third and fourth bars represent the effect of antagonist alone, A) H7 
(IOjiM) or B) staurosporine (0.5|iM), and the effect of antagonist + PMA 
respectively.
Responses are expressed as a percentage of the initial response obtained in each 
tissue. Each point represents the mean ± s.e.m. (n=5). Statistically significant 
differences between test responses and paired controls (*), between (antagonist + 
PMA) and PMA alone (f), and between (antagonist + PMA) and antagonist alone 
(#) were assessed by ANOVA, 95% confidence limits.
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Table .6,2
The effect of antagonists on PMA-induced potentiation of response to 16Hz EFS 
M ean  (s.e .m .)%  o f  in itia l response  a t 60  m inu tes in to  incubation  period
Atropine Verapamil H7 Staurosporine 
Control 85 (5) 91 (6) 82 (4) 100 (6)
PMA 250 (60) 185 (37) 139 (12) 137 (13)
Antagonist 5 (4) 48 (3) 60 (8) 54 (7)
PMA + Antagonist 8 (3) 45 (11) 90 (6) 50 (17)
Table 6,3
The effect of antagonist on the PMA-induced potentiation of response to EFS 
S ign ifican t d ifferences a t 60  m inutes into incubation  period
Control /  PMA alone
Atropine
•
Verapamil
•
H7
•
Staurosporine
•
Control /  antag. alone • O O •
Control /  PMA+antag. • O • •
PMA /  antag. • • • •
PMA /  antag. + PMA • • o •
antag. /  antag. + PMA O o • O
(Significance assessed by ANOVA: #  significant difference; O no significant difference; 95%C.I.)
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Figure 6.6
Effect of antagonists on the PMA-induced potentiation of response to 16Hz EFS. 
Bars represent responses to EFS in control tissues (C) and those treated with PMA 
(P), an antagonist (atropine [A], verapamil [V], H7[H] or staurosporine [S]), or 
both.
Responses are expressed as a percentage of the initial response obtained in each 
tissue. Bars are mean ± s.e.m., the number of experiments in each group are shown 
within the bars. Statistically significant differences between test responses and paired 
controls (*), between (antagonist + PMA) and PMA alone (t) , and between 
(antagonist + PMA) and antagonist alone (#) were assessed by ANOVA, 95% 
confidence limits.
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6.4 Cumulative concentration response curves to acetylcholine
The sensitivity and the maximum size of response of rabbit secondary bronchi to ACh 
is reproducible with time. In two cumulative concentration response curves (CCRC) 
to ACh in the same tissue, seperated by 45 minutes (Fig. 6.7), neither the response 
to the highest concentration tested (Tmax; 30(iM ACh) nor the sensitivity of the tissue 
was altered; pD2 values obtained for the first and second curves (5.28 (0.12) & 5.28 
(0.08) respectively) were not significantly different (n=12; p>0.05).
6.5 Effect o f PMA on ACh CCRC
Incubation with lpM  PMA 45 minutes prior to starting the second CCRC had no 
significant effect on the sensitivity of the tissue (pD2 values for pre- and post­
incubation curves were 5.51 (0.11) and 5.44 (0.10) respectively; n=7, p>0.05) or on 
the maximum contractile response to ACh (Tmax: 1.014 (0.255) and 0.980 (0.107) 
grams respectively. Fig 6.8).
Following 45 minutes incubation with 10|iM PMA responses to individual 
concentrations of ACh (0.3, 1, 3, lOpM) within the CCRC were significantly 
increased in test tissues (Fig. 6.9; n=8, p<0.05). There was no significant increase in 
the contraction produced by the maximum concentration of ACh employed (Tmax:
1.337 (0.159) grams), but PMA produced a small leftward shift, increasing the mean 
pD2 value of test tissues from 5.51 (0.15) to 5.80 (0.15) with the result that the 
second curve was significantly more sensitive than its corresponding time control 
(pD2: 5.25 (0.04); p<0.05).
Correcting the second CCRC test figures for the small change in the control 
responses with time confirmed these findings (Fig. 6.10). There was no significant 
increase in the maximum response produced in test tissues but there was a
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potentiation of response to sub-maximal concentrations of ACh (1, 3 & IOjiM; n=8, 
p<0.05) and a leftward shift; test tissue pD2  values were significantly greater than 
those of the time controls (5.75 (0.18) and 5.24 (0.04) respectively, p<0.05).
In the original experiments (Figs. 6.7-6.10) the CCRC extended from concentrations 
of InM to 30pM ACh. Higher concentrations were not initially examined due to the 
possibility of compromising the contractile apparatus of the preparation. Exceeding a 
dose of approximately 95% of maximum may do irreversible damage to the 
preparation (Blattner et al, 1978). However, the curves were subsequently extended 
to 300|iM ACh in another six pairs of bronchi without any apparent damage to the 
test tissues. These experiments produced a similar pattern of potentiation. PMA 
significantly increased the response to submaximal concentrations (1, 10 & 30|iM) of 
ACh but produced no significant increase in response to 100 or 300|iM ACh and no 
significant shift in the pD2 value (Fig. 6.11).
Combining all the available data (Fig. 6.12; n=14), PMA produces a potentiation of 
response at 0.1-30fiM ACh.
6.6 Effect o f  PMA on ACh CCRC in low calcium Krebs
In contrast to the above reports, IOjiM PMA did not significantly increase the 
responses within the ACh CCRC in nominally calcium-free Krebs (Fig. 6.13). 
Incubation with PMA did not produce a significant shift in pD2 value (T1 4.97(0.14); 
T2 4.81(0.24)). However, PMA did prevent the rightward shift in sensitivity shown 
by the controls in low calcium Krebs (pD2 values: C l 5.05(0.13); C2 4.37(0.14)). 
This shift was significant (p<0.05) and indicates a reduction in sensitivity to ACh of 
the control tissues. Comparing the size of the shift within individual control and test 
tissues a significant difference was seen (n=5, p<0.01). Incubation with 10p.M PMA, 
therefore, appears to halt the desensitization of the tissue rings. Tmax was not 
significantly reduced by incubation in calcium free Krebs.
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Effect of time on the response of rabbit secondary bronchi to ACh. Open symbols 
(O) represent initial ACh cumulative concentration response curves (CCRC) in 12 
tissues. Filled symbols (# )  represent the responses to a second ACh CCRC in the 
same tissues 45 minutes later. Responses are expressed A) as grams tension or B) as 
a percentage of the largest response obtained in each first curve. Statistical 
comparisons were made between the responses obtained in the 1st and 2nd curves at 
each concentration (paired t-test; n=12).
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Effect of l|iM  PMA on the response of rabbit secondary bronchi to ACh. Open 
symbols (0 ,A )  represent responses to an ACh cumulative concentration response 
curve (CCRC) in two sets of paired tissues. Filled symbols represent the responses 
to second CCRCs in the presence (A) or absence (# )  of lpM  PMA. Responses are 
expressed A) as grams tension or B) as percentages of the largest response obtained 
in each first curve. Each point represents the mean±s.e.m. (n=7). Statistical 
comparisons were made between the responses obtained in the 2nd curve of paired 
tissues at each concentration (paired f-test, *p<0.05)
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Effect of 10|iM PMA on the response of rabbit secondary bronchi to ACh. Open 
symbols (0 ,A ) represent responses to an ACh cumulative concentration response 
curve (CCRC) in two sets of paired tissues. Filled symbols represent the responses 
to second CCRCs in the presence (A) or absence (# )  of 10|iM PMA. Responses 
are expressed A) as grams tension or B) as percentages of the largest response 
obtained in each first curve. Each point represents the mean±s.e.m. (n=8). 
Statistical comparisons were made between the responses obtained in the 2nd curve 
of paired tissues at each concentration (paired r-test, *p<0.05)
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Effect of 10}iM PMA on the response of rabbit secondary bronchi to ACh 
correcting for changes in control tissues with time. Open symbols (A ,0 )  represent 
responses to an ACh cumulative concentration response curve (CCRC) in two sets 
of paired tissues. Filled symbols show the responses to second CCRCs in the 
presence (A) or absence (# )  of IOjiM PMA. Results are expressed as a corrected 
percentage of the maximum response to ACh in the first CCRC. Each point 
represents the mean ± s.e.m.(n=8). Statistical comparisons were made between the 
responses obtained in the 2nd curves of paired tissues at each concentration (paired 
r-test; *p<0.05).
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Figure 6.11
Effect of PMA on a cumulative concentration response curve (CCRC) to ACh in 
rabbit secondary bronchi. Open symbols represent initial control CCRCs in two 
sets of paired tissues (0 ,A ) .  Filled symbols show the responses to second 
CCRCs in the presence (A) or absence ( # )  of lOpM PMA. Responses are 
expressed as percentages of the largest response obtained in each first curve. 
Statistical comparisons were made between the responses obtained in the second 
curve of paired tissues at each concentration (paired r-test, *p<0.05, **p<0.01; 
n=6).
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Effect of PMA on a cumulative concentration response curve (CCRC) to ACh in 
rabbit secondary bronchi. Open symbols represent initial control CCRCs in two 
sets of paired tissues (0 ,A ) .  Filled symbols show the responses to second 
CCRCs in the presence (A) or absence ( # )  of 10p.M PMA. Responses are 
expressed as grams tension produced. Each point represents the mean ± s.e.m. 
(n=14). Statistical comparisons were made between the responses obtained in the 
second curve of paired tissues at each concentration (paired f-test, *p<0.05,
**p<0.01).
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Figure 6.13
Effect of IOjiM PMA on the response of rabbit secondary bronchi to ACh in a low 
calcium environment. Open symbols ( A ,0 )  represent responses to an ACh 
cumulative concentration response curve (CCRC) in two sets of paired tissues. 
Filled symbols show the responses to second CCRCs, in low calcium Krebs, in the 
presence (A) or absence (# )  of lOpM PMA. Results are expressed A) as grams 
tension or B) as a percentage of the largest response obtained in each first curve. 
Each point represents the mean ± s.e.m.(n=5). Statistical comparisons were made 
between the responses obtained in the 2nd curves of paired tissues at each 
concentration (paired r-test; *p<0.05).
6.7 Sub-maximal dose studies: responses to ACh
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The contractile response of rabbit secondary bronchi to ACh was sustained and 
reproducible with time, as illustrated below. The response produced by lOpM ACh 
(0.743(0.11) grams) was equivalent to 56% of the maximum contraction to ACh in 
this tissue (1.316(0.15) grams).
Time course of the submaximal dose experiments.
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6.8 Effect o f PMA on responses to ACh.
Incubation with 10p.M but not lp.M, PMA potentiated the contractile response of 
secondary bronchi to a single sub-maximal concentration of lOpM ACh (Fig. 6.14). 
lpM  PMA produced an increase in response to ACh of 39(14)% but this failed to 
reach significance as controls showed a slight increase of 11(6)% with time (n=6; 
p>0.05). In contrast, 45 minutes incubation with 10|iM PMA increased the response 
to lOjuM ACh to 169(20)% of its initial value which was significantly (p<0.01; n=8) 
greater than the time control 97(11)%. Following washout with fresh KH solution,
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Figure 6.14
Effect of PMA on the response of rabbit secondary bronchi to a submaximal 
concentration of ACh. Open bars represent time control responses to IOjiM ACh, 
hatched bars represent test responses at 45 minutes into incubation with A) lpM  
or B) 10|iM PMA. Responses to two subsequent contractions to 10|iM ACh at 15 
minute intervals are also shown.
Each point represents the mean ± s.e.m. (n=7-8). Statistically significant 
differences between control responses and those in the presence of PMA are 
represented by *p<0.05, **p<0.01, Student’s f-test.
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subsequent responses of test tissues to IOjiM ACh remained raised (130 (17)% and 
132 (15)% of initial response) but were not significantly greater than the time control 
values 100 (10)%, and 98 (11)% respectively (n=8; p>0.05).
6.9 Effect o f antagonists on the potentiation o f response to ACh
Nifedipine
Nifedipine (0.3|iM) inhibited the potentiation of response to lOpM ACh by 10|iM 
PMA (Fig. 6.15). In this series of 5 experiments PMA significantly increased the 
response of test tissues to ACh to 135(6.5)% of their initial size while controls 
remained steady at 102(7)% (p<0.05). Incubation with nifedipine alone had no effect 
on the size of reponse to ACh (100(5)%) but the dihydropyridine abolished the 
subsequent potentiation by PMA; test responses reached 84(13)% of their initial value 
which was not significantly different from the time control (p>0.05).
Verapamil
Verapamil (10fiM) itself reduced the response to IOjiM ACh by 38(10)% but this 
failed to reach significance (p>0.05, ANOVA). PMA alone significantly increased 
the response of test tissues to 170(18)% (n=5,p<0.05) of their initial value, while 30 
minutes pre-incubation with verapamil abolished this potentiation, responses reached 
59(10)% of their initial size which was (somewhat surprisingly) not significantly 
different from the control value of 95(6)% (ANOVA) (Fig. 6.15)
Amiloride
Amiloride (100|xM) attenuated but did not significantly inhibit the potentiation of 
response to 10|iM ACh by PMA (Fig. 6.16). In the this series of experiments (n=7),
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PMA increased the response of test tissues to 155(16)% of their initial value while 
control tissue responses remained steady at 108(4)%. Amiloride itself reduced the 
response to 86(11)% and in the presence of this inhibitor the increase produced by 
PMA, 123(20)%, failed to reach significance. However this response was not 
significantly different from that of PMA alone (p>0.05) and may therefore have 
depressed rather than abolished the response to PMA.
Indomethacin
Indomethacin (IOjiM) had no effect on the PMA potentiation of response to ACh 
(Fig. 6.16). In this series of experiments, PMA produced an increase in response to 
148(5)% of the initial value (n=5; p<0.05). Responses in the presence of 
indomethacin (122(2)%) were also significantly greater than time control values 
(91(8)%). In the presence of both indomethacin and PMA responses reached 
157(18)% of their initial value and were significantly different from both control 
responses and those in the presence of indomethacin alone, but not from those in the 
presence of PMA alone.
H7
Incubation with H7 (IOjiM) had no significant effect on the response (102(9)%) to 
ACh. PMA produced an increase in response of test tissues to 162(18)% of initial 
values, which was significantly different from the mean time control value of 
104(10)% (n=7; p<0.05; Fig. 6.17). The response in the presence of both PMA and 
H7 (137(19)%) was significantly greater than that in the presence of H7 alone, but 
was not significantly greater than time control values or significantly smaller than the 
increase with PMA alone (i.e.comparing control values with those in the presence of 
both drugs the results suggest H7 has abolished the PMA effect. However,
comparing H7 alone with H7 plus PMA there is evidently a PMA-induced increase in 
size of response despite the presence of H7)
Staurosporine
Staurosporine (0.5|iM) produced a reduction in the response to ACh (Fig. 6.17). In 
this set of 5 experiments, staurosporine significantly reduced the response to 10pM 
ACh to 35 (5)% (p<0.05) of its initial value while PMA produced an increase to 
144 (5)% (p<0.05), and control responses remained steady at 109 (8)% of their initial 
value. In the presence of both staurosporine (0.5fiM) and PMA responses reached 
82(8)% of their initial value, which was significantly different from those in the 
presence of either drug alone (n=6; p<0.05, ANOVA).
The results of the antagonist studies are summarised in tables 6.4 & 6.5 and in figure
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Figure 6.15
Effect of calcium channel blockade on the PMA-induced potentiation of response 
to ACh in rabbit secondary bronchi. Open bars represent time control responses 
to IOjiM ACh. Hatched bars represent test responses at 45 minutes into 
incubation with 10|J.M PMA. Third and fourth bars represent the effect of 
antagonist alone, A) nifedipine (0.3pM) or B) verapamil (IOjiM), and the effect 
of antagonist + PMA respectively.
Each point represents the mean ± s.e.m. (n=5-6). Statistically significant 
differences between test responses and paired controls (*), between (antagonist + 
PMA) and PMA alone ( t) , and between (antagonist + PMA) and antagonist 
alone (#) were assessed by ANOVA, 95% confidence limits.
F ig u re  6.16
Effect of amiloride and indomethacin on the PMA-induced potentiation of 
response to ACh in rabbit secondary bronchi. Open bars represent time control 
responses to IOjiM ACh. Hatched bars represent test responses at 45 minutes into 
incubation with 10|iM PMA. Third and fourth bars represent the response in the 
presence of A) amiloride (lOOfiM) or B) indomethacin (10pM), and the effect of 
antagonist + PMA respectively.
Results are expressed as a percentage of the initial response to 10pM ACh. Each 
point represents the mean ± s.e.m. (n=5-7). Statistically significant differences 
between test responses and paired controls (*), between (antagonist + PMA) and 
PMA alone (f), and between (antagonist + PMA) and antagonist alone (#) were 
assessed by ANOVA, 95% confidence limits.
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F ig u re  6.17
Effect of inhibition of PKC on the PMA-induced potentiation of response to ACh 
in rabbit secondary bronchi. Open bars represent time control responses to 10pM 
ACh. Hatched bars represent test responsse at 45 minutes into incubation with 
lOfiM PMA. Third and fourth bars represent the effect of inhibitor alone, A) H7 
(10|iM ) or B) staurosporine (0.5pM), and the effect of inhibitor + PMA 
respectively.
Each point represents the mean ± s.e.m. (n=5-7). Statistically significant 
differences between test responses and paired controls (*), between (antagonist + 
PMA) and PMA alone ( t) , and between (antagonist + PMA) and antagonist 
alone (#) were assessed by ANOVA, 95% confidence limits.
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Table 6.4
Effect of antaeonists on the potentiation of response of rabbit secondary 
bronchi to lOuM ACh bv lOpM PMA.
Expressed as a percentage (±sem) of the initial response to 10|iM ACh(n=5-7)
Antagonist Control PMA Antagonist PMA+Antag
0.3 pM  Nifedipine 102 (7) 135 (7) 100 (5) 84(13)
10 jiM Verapamil 95 (6) 170(18) 62 (10) 59(10)
10 pM Indomethacin 91 (8) 148 (5) 122 (2) 157 (18)
lOOpM Amiloride 108 (4) 155 (16) 86(11) 123 (20)
10 pM H 7 104 (10) 162(18) 102 (9) 137 (19)
0.5pM Staurosporine 109 (4) 144 (5) 35 (5) 82 (8)
Table 6.5
Effect of antagonists on the potentiation of response of rabbit secondary 
bronchi to lOfiM ACh bv lOpM PMA.
(significant difference assessed by ANOVA test, 95% C.L.)
Nifedipine Verapamil Amiloride Indomethacin H7 Staurosporine
Control /  PMA alone • • • • •
Control /  antag. alone O o o • o
Control /  PMA+antag. O o o • o
PMA /  antag. • • • o •
PMA /  antag. + PMA • • o o o
antag. /  antag. + PMA o o o • •
( •  significant difference; O no significant difference)
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Figure 6.18
Effects of antagonists on the PMA-induced potentiation of response to lOpM 
ACh. Bars represent responses to ACh in control tissues (C) and those treated 
with PMA (P), an antagonist (verapamil [V], nifedipine [N], indomethacin [I], 
amiloride [A], H7[H] or staurosporine [S]), or antagonist plus PMA.
Bars are mean ± s.e.m., the number of experiments in each group is shown 
within the bars. Significant differences between "antagonist" and paired controls 
(*), between (antagonist + PMA) and PMA alone (t) , and between (antagonist + 
PMA) and antagonist alone (#) were assessed by ANOVA, 95% confidence 
limits.
6.10 Sub-maximal dose studies: responses to histamine
Responses to histamine in rabbit secondary bronchi are subject to severe 
tachyphylaxis. In order to obtain reproducible responses tissues were thoroughly 
washed in fresh Krebs and allowed to rest for 30minutes between doses of histamine. 
Under these conditions, 10|iM Histamine produced a contraction of 0.435 (0.08) 
grams, approximately 65% of the maximum contraction obtained to histamine in this 
preparation ( 300pM; 0.661 (0.11) grams)
6.11 Effect o f  PM A on response to histamine
45 minutes incubation with lOfiM PMA potentiated the response to 10|iM histamine 
in rabbit secondary bronchi (Fig. 6.19). The mean response to histamine was 
increased to 157(12)% of the initial response which was significantly greater than the 
time control, 108(3)% (p<0.05; n=5). Interestingly, this effect was not reversed by 
washing. Second and third responses were also significantly increased to 162(11)% 
and 152(13)%, with time controls remaining steady at 100(3) and 108(12)% 
respectively (p<0.05).
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Effect of PMA on the response of rabbit secondary bronchi to a submaximal 
concentration of histamine. Open bars represent time control responses to 10|iM 
histamine, hatched bars represent the effect of 10|iM PMA. Responses to 
histamine are shown at 45 minutes into incubation with PMA and after two 
succesive washes in fresh Krebs solution. Bars represent the mean ± s.e.m. 
(n=5). Statistically significant differences between control responses and those in 
the presence of PMA are represented by *p<0.05, *p<0.01, Student's r-test.
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6.12 Responses to EFS and to ACh in human bronchial muscle
Human airway smooth muscle responded to EFS (16Hz) with a biphasic contraction; 
no relaxation was seen. Size of response to EFS was variable but reproducible within 
tissues. In eight tissues the mean response was 210 (±70) mg (c.f. 630±100mg in 
rabbit bronchi).
Responses to ACh (lOfiM) were larger than to EFS, and were sustained. In eight 
tissues ACh produced a mean contraction of 360 (±30) mg (c.f. 743±1 lOmg in rabbit 
bronchi).
6.13 Effect o f  PMA on responses to EFS and ACh
PMA potentiated the response to EFS at 16Hz in human airway (Fig. 6.20). The 
potentiation followed a similar time scale to that seen in rabbit bronchi, the responses 
increasing in size steadily over a period of 45-60 minutes. At 60 minutes into 
incubation with 10pM PMA responses in test tissues were increased to 224 (26)% of 
their initial value. Test tissue responses were significantly elevated (n=5, p<0.01); 
time control tissues produced responses of 91 (7)% of their initial value.
PMA also potentiated the response to a submaximal concentration of ACh in human 
airway (Fig. 6.21). Responses to 10pM ACh were increased to 260 (40)% of their 
initial value after 60 minutes incubation with lOpM PMA. These responses were 
significantly greater than their respective time control responses of 132(26)% (n=5, 
p<0.05). However, following washout in fresh Krebs, second and third responses 
did not differ significantly from control values.
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Effect of PMA on the response of human bronchi to electrical field stimulation 
(EFS). Open symbols represent time control responses to 16Hz EFS. Closed 
symbols represent test responses during incubation with IOjiM PMA.
Results are expressed as a percentage of the initial response to 16Hz EFS. Each 
point represents the mean ± s.e.m. (n=5). Statistically significant differences 
between responses of paired tissues in the presence or absence of PMA are 
represented by *p<0.05, *p<0.01, Student's r-test.
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Effect of PMA on the response to of human bronchi to endogenous and 
exogenous ACh. Open bars represent time control responses to A) 16Hz EFS or 
B) 10pM ACh. Hatched bars represent test responses at 60 minutes into 
incubation with lOfiM PMA.
Results are expressed as a percentage of the initial response to A) 16Hz EFS or 
B) 10|iM ACh. Each bar represents the mean ± s.e.m. (n=5). Statistically 
significant differences between responses of paired tissues in the presence or 
absence of PMA are represented by *p<0.05, **p<0.01, Student's r-test.
Section 7
DISCUSSION
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7.0 Discussion
In this study PMA was found to potentiate excitatory responses in bronchial smooth 
muscle. The basis for the use of PMA was that it would activate smooth muscle 
PKC. However the phorbol esters are known to have actions that are not mediated by 
PKC (section 4.6). While indirect confirmation of the involvement of PKC in the 
response to PMA was provided by the inhibition of its effects by staurosporine and 
the more limited attenuation by H7, these compounds are not specific inhibitors of 
PKC and may well have actions on other cellular enzymes (section 7.7). Nevertheless 
copurification of kinase activity and phorbol ester binding has shown that PKC is the 
major phorbol ester receptor in cells (section 4.5) and the results will therefore be 
discussed in the context of what might be expected if facilitation by PMA were due to 
activation of PKC, although activation of some other, as yet unknown, system cannot 
be excluded.
7.1 Effect o f  PMA on response to EFS
At concentrations that produced no increase in baseline tension, PMA potentiated the 
contractile response to electrical field stimulation (EFS) in both rabbit and human 
airways. While it is not known at what frequency the nerves are stimulated in vivo, a 
time- and concentration-dependent potentiation of response was produced by PMA 
(10|iM) across a range of frequencies (4, 16 & 30Hz).
Phorbol esters have been demonstrated to produce an increase in tone in vascular and 
airway smooth muscle preparations. However in the rabbit and human bronchial 
preparations this effect was rarely observed at concentrations below lOOpM. In 
contrast, lower concentrations of PMA (0.1-10pM) produced a gradual contraction in 
rat and rabbit aorta (Danthuluri & Deth, 1984; Spedding, 1987), in rabbit ear arteries 
(Forder, 1985) and in bovine and guinea-pig tracheal smooth muscle (Park &
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Rasmussen, 1989; Souhrada & Souhrada, 1989a). Rabbit bronchial smooth muscle, 
therefore, appears to be less sensitive to the contractile effects of phorbol esters than 
the above tissues. There is a large degree of variability between species and tissue 
preparations, however, as illustrated by the findings of Schramm & Grunstein (1989) 
that a phorbol ester (10pM 12-deoxyphorbol 13-isobutyrate; DPB) produced a 
relaxation, rather than a contraction, in rabbit trachea, and those of Menkes et al
(1986) who demonstrated both contraction and relaxation to phorbol esters (DPB and 
phorbol-12,13-diacetate) in guinea pig trachea.
Following an initial latent period, PMA produced a progressive increase in the 
response to EFS which reached a maximum at 45-60 minutes into the phorbol ester 
incubation. A similar delayed action has been reported previously in the responses of 
vascular tissues to phorbol esters. A latent period was observed between the addition 
of phorbol ester and the resultant slow contraction in rat aorta (Danthuluri & Deth, 
1984) and rabbit ear artery (Forder et al., 1985). In airway smooth muscle, an 
immediate response to PMA was seen in guinea pig trachea (Souhrada & Souhrada, 
1989a). However a delay of up to 120 minutes was reported in bovine trachea (Park 
& Rasmussen, 1985). Other documented effects of phorbol esters, such as their 
inhibitory effect on al-adrenoceptor-mediated responses, follow a similar time scale 
(Danthuluri & Deth, 1984). While the delay may simply be due to the time necessary 
for the phorbol ester molecule to cross the plasma membran, Forder et al (1985) 
reported that agents which increased the calcium influx could significantly reduce this 
delay and suggested that increased levels o f intracellular calcium influenced the 
activity of activated protein kinase C. It is possible that the concentration of calcium in 
a domain just below the plasma membrane is an important modulator of the activity of 
PKC (Rasmussen et al., 1987) and that the delayed response in rabbit bronchi may be 
due to a lag time in calcium influx into this submembrane region. Alternatively, it is 
possible that the relatively high concentration of PMA employed (10|iM) immediately 
down-regulates the enzyme and that it is not until large amounts of phorbol ester enter
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the cell that the negative effects are overridden by the positive effects. The short 
length of the timelag, however, does not suggest that down-regulation is taking place. 
Rather, it is more likely that the negative feedback of PKC on the formation of 
phosphatidylinositides initially opposes the positive effects on agonist-induced 
contraction which subsequently become dominant.
The degree of potentiation was concentration-dependent suggesting a progressively 
higher level of activation of the available PKC. A 1:1 relationship is postulated to 
exist between molecules of DAG (or PMA) and of PKC in the presence of excess 
phospholipid and at physiological calcium concentrations (Nishizuka, 1984, 1986; 
Section 4.3). It is therefore possible that the concentration-dependent increases in 
response reflect increasing numbers of activated molecules of PKC.
Significant potentiation was produced only by the higher concentrations of PMA (1- 
lOOpM) with little effect being observed at lower concentrations. As noted above, 
effects of phorbol esters have previously been reported at lower concentrations. 
However there is a large amount of variability in the potency of phorbol esters, even 
between preparations from the same species as demonstrated by Wagner (1987) in 
vascular preparations from the rabbit; while the main part of the concentration 
response curve was covered by l-30nM  phorbol dibutyrate (PDBu) in the basilar 
artery, the renal and saphenous arteries required between 30nM-3|iM and 0.1-3|iM 
PDBu respectively. However, the concentration of PMA employed (lOpM) in the 
present study has been shown to be optimal for the contractile response in several 
smooth muscle preparations (Danthuluri & Deth, 1984; Chattergee & Tejada, 1986; 
Souhrada & Souhrada, 1989a).
That activation of PKC should increase the response to EFS initially seems 
inconsistent as the enzyme is understood to play a part in the sustained phase of 
contraction (Rasmussen & Barratt, 1984; section 3.4) while the response to EFS is
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immediate and phasic. However, PKC is reported to increase calcium and sodium 
fluxes in airway smooth muscle (Souhrada & Souhrada, 1989a) and the alteration of 
intracellular calcium levels might itself enhance the sensitivity of the contractile 
proteins. Activated PKC may alternatively directly 'prime' the contractile apparatus 
such that the response to subsequent EFS-induced agonist binding would be 
enhanced. It has been suggested that activated PKC enhances the calcium sensitivity 
of the contractile proteins themselves (Rodger, 1986; Itoh et al., 1988) or that it might 
render the cell ready to function when calcium becomes available (Nishizuka, 1984).
7.2 Site o f  action o f  PMA.
Addition of the muscarinic antagonist atropine abolished control responses to EFS as 
well as the potentiation of response by PMA, suggesting that the potentiated response 
was mediated primarily through cholinergic mechanisms. Muscarinic receptors are 
found predominantly in proximal airways and have been identified in airway ganglia, 
on cholinergic nerve terminals and on airway smooth muscle (section 2.1). The 
potentiation of response to EFS by PMA could therefore result from action of the 
phorbol ester on the coupling of the pre- or post-junctional muscarinic receptors, or a 
combination of both. The potentiation was also inhibited by verapamil indicating that 
Ca2+ influx may be involved in the facilitatory effect of PMA on the contraction to 
EFS.
7.3 Possible pre-junctional effects
In the airways release of ACh from vagal fibres is limited by inhibitory M2 
muscarinic receptors on post-ganglionic parasympathetic nerves (Fryer & MacLagan, 
1984) which have been demonstrated in humans (Minette & Barnes, 1988). An 
uncoupling o f these pre-junctional autoregulatory receptors by PMA could
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significantly increase the output of ACh upon nerve stimulation; inhibition of the M2 
receptor with the specific blocking-agent gallamine, results in a ten-fold potentiation 
of vagally-induced bronchoconstriction (Fryer & MacLagan, 1984).
Alternatively, PMA may block the action of an inhibitory co-transmitter. VIP is 
known to co-exist with ACh in cholinergic nerves, as do galanin and PHI (section 
2.1), and reduces the contractile response to both ACh and to EFS in vitro, 
particularly at higher frequencies (Palmer et al., 1985b). All three peptides are potent 
bronchodilators and may act as an in-built braking system on the ACh-induced 
contraction of smooth muscle. An inhibition of this mechanism (e.g. of the synthesis, 
storage or release of these peptides), might result in an exaggerated response to 
cholinergic stimulation, such as that produced by PMA in these preparations.
There are many examples in the literature of phorbol ester-mediated enhancement of 
neurotransmitter release although these have been mainly in brain tissue; Nichols et 
al. (1987) report potentiation by phorbol esters of calcium-dependent release of all 
neurotransmitters studied (ACh, noradrenaline (NA), gamma-aminobutyric acid, 
serotonin, dopamine and aspartate) in all areas of the rat brain studied (cortex, 
hippocampus and corpus striatum).
Tanaka et al. (1986) demonstrated an increased response in the presence of PMA to 
Ca2+-dependent depolarisation-evoked release of [3H]ACh in guinea pig caudate 
slices. The effect was potentiated by calcium ionophore (A23187) and antagonised 
by H7 suggesting the increased response was mediated via PKC. This mechanism is 
supported by Nichols et al. (1987) who showed that only phorbol esters that activate 
PKC (p-isomers) were effective in enhancing neurotransm itter release and 
Daschmann et al. (1988) who demonstrated that the potentiation of release could be 
inhibited by the protein kinase inhibitors staurosporine and H7. Similarly
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staurosporine, and to a lesser degree, H7, inhibited the potentiation of response to 
EFS by PMA in rabbit bronchi (section 65).
PMA produced an enhancement of depolarisation-induced release of [3H]NA from 
cultured neuronal cells (Matthies et al., 1987); however chronic phorbol ester 
treatment resulted in loss of the potentiating effect of PMA. This apparent 
desensitisation of neurotransmitter receptors has recently been studied by Dillon- 
Carter and Chuang (1989) who found that incubation of cultured cerebral granule 
cells with saturating concentrations of carbachol, histamine, NA or serotonin caused a 
time-dependent desensitisation of the cells to that agonist, while incubation with PMA 
desensitised the cells to all of the above agonists. Measurement of the PLC activity of 
the cells revealed that PMA attenuated the enzyme's activity and thereby down- 
regulated the PLC-coupled receptors. A further effect on the PI pathway was 
demonstrated in a recent experiment by Weiss et al (1989) who found that incubation 
with PDBu attenuated carbachol-stimulated inositol monophosphate (IP) production 
in cultured striatal neurons. Thus, a secondary, long term effect of PKC activation 
may be mediated via modulation of PLC and the subsequent inhibition of signal 
transduction via inhibition of the agonist-induced production of inositol 
phospholipids. In the rabbit airway preparation the potentiation of response to EFS 
by PMA was maximal at approximately 60 minutes into incubation but subsequently 
decreased to initial levels, or slightly below, over 120 minutes; this effect could be 
elicited by inhibition of the PI pathway, or by down-regulation of PKC itself.
7.4 Mechanism o f  pre-junctional effect
Wakade e ta l. (1985) demonstrated in [3H]NA-loaded rat sympathetic neurons that 
the facilitatory effect of PMA on EFS-evoked NA release was unaffected by the 
presence of inhibitors of neuronal and extraneuronal uptake, or by removal of 
negative feedback inhibition by pre-synaptic a-receptors. Similarly, Allgaier et al.
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(1987) showed that the enhanced release of NA from hippocampal slices was calcium 
dependent and that it was not due to an effect on the autoinhibitory feedback system 
as the enhancing effects of yohimbine (an a 2-antagonist) were increased in the 
presence of PMA, while the inhibitory effects of clonidine (an a 2-agonist) were 
unaffected. This group later demonstrated that the phorbol ester-induced facilitation of 
NA release was similarly independent of pre-synaptic changes in Na+, K+ or CL" 
conductance (Huang et al., 1988).
The above results suggest that the facilitatory effect of PMA on EFS is not due to an 
uncoupling of the pre-junctional autoinhibitory M2 receptors or to effects on neuronal 
or extraneuronal uptake of neurotransmitter. They indicate that PMA, probably via 
activation of PKC, exerts a dual effect; firstly facilitating and secondly inhibiting 
neurotransmitter release. PMA may act synergistically with calcium to increase 
neurotransmitter release; phorbol esters have been shown to enhance calcium- 
dependent depolarisation-induced neurotransmitter release by producing a marked 
decrease in the concentration of Ca2+ needed to provoke the release (Zurgil & 
Zisapel, 1985) and studies in chick sympathetic neurons suggest that activation of 
PKC enhances Ca2+ accumulation, which in turn leads to the facilitation of 
neurotransmitter release (Malhotra et al., 1988).
The observation in the rabbit airway preparation that verapamil inhibited the PMA- 
induced potentiation supports the hypotheses that calcium influx is necessary for full 
activation of PKC and that synergism between activated PKC and Ca2+ is important 
in the release response.
In order to examine whether PMA is having such a pre-junctional effect in the 
bronchial smooth muscle preparation, detailed studies of neurotransmitter output on 
nerve stimulation in the presence and absence of PMA would be needed. As atropine 
does not differentiate between receptor sub-types and blocks both M2 and M3
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receptors, it provides no information on the site of action of PMA or on the possible 
involvement of a co-transmitter or regulatory neuropeptide. Alternatively, PMA could 
exert its effect via a post-junctional mechanism and it was decided to investigate this 
possibility further.
7.5 Possible post-junctional ejfects
The increased response to EFS in the presence of PMA could be the result of an 
increased number of M3 receptors on the airway smooth muscle, an increased affinity 
of these receptors for ACh, or post-receptor synergism. In order to assess the 
contribution of post-junctional mechanisms to the PMA-induced potentiation, its 
effect on the direct addition of exogenous ACh to the rabbit bronchi preparation was 
examined. Cumulative concentration response curves (CCRC) were obtained to 
provide detailed information of the sensitivity and responsiveness of the preparation 
in the absence and presence of PMA.
Hyperresponsiveness in airway smooth muscle can be due to the muscle cell 
responding to a contractile agonist at lower concentrations (type I sensitivity), or 
producing a greater response to "normal" agonist concentrations (type II sensitivity), 
or both of these. PMA potentiated responses to certain concentrations within the 
ACh CCRC but while it produced a small shift in the the curve, it did not produce an 
increase in response to the maximum concentration employed. These effects are most 
typical of type II (also known as post-junctional or non-deviation) sensitivity and 
indicate a synergism beyond the receptor rather than an increase in the sensitivity or 
number of receptors. Post-receptor changes in excitation-contraction coupling or in 
the contractile apparatus itself could account for the potentiation seen; possible 
mechanisms include increased release of Ca2+ on agonist stimulation, activation of a 
greater number of contractile proteins or activating enzymes, increased activity of 
crossbridges or abnormal length-tension relationships. Similarly, this type of
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response could be produced by improved cell-to-cell coupling, perhaps due to an 
increased number of gap-junctions. The results obtained from the rabbit preparation 
do not implicate Type I sensitivity in the PMA/PKC effect, thus mechanisms 
generating this type of sensitivity (such as depolarisation of the membrane or changes 
in receptor affinity or number) are unlikely to be of consequence in rabbit bronchial 
smooth muscle.
The shift in sensitivity of the curve was significant but very small. Under these 
circumstances it is often useful to examine the effect of the drug on submaximal 
concentrations of the contractile agonist; thus the effect of incubation with PMA on 
the response to 10|iM ACh, one of the concentrations to which the response was 
increased within the CCRC, was examined. The contractile response elicited by 
10|iM ACh (760mg) corresponds approximately to the EC50 of ACh in this 
preparation, and was increased by approximately 70% in the presence of PMA. This 
effect was reversed by repeated washes in oxygenated Krebs solution, confirming 
that the phorbol ester was having a non-toxic, reversible effect on the smooth muscle.
The response obtained to 16Hz EFS similarly corresponds to approximately 50% of 
the maximum contractile response to ACh. PMA (lOpM) increased the response to 
EFS by 34 (±6) % and that to exogenous ACh by 69 (±20) %, indicating that a 
substantial proportion of the PMA effect may be mediated via post-junctional 
mechanisms. A similar pattern was observed in human tissue substantiating these 
findings; following incubation with PMA, the potentiation of response to exogenous 
ACh was greater that that to EFS, an increase of 160 (±40)% and 124 (±26)% 
respectively.
The importance of post-junctional mechanisms in the phorbol ester effect was 
confirmed by the observation that the potentiation was not limited to cholinergic 
stimuli. PMA (10|iM) increased the response of rabbit bronchi to a single
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submaximal concentration of histamine (10pM; approximately EC65) by 57%, an 
effect that was not significantly reversed by subsequent washing over the period 
tested. This result strongly supports a change in smooth muscle biochemistry’ rather 
than an effect of PMA on (two sets of) receptors. Both histamine and ACh utilize the 
phosphatidylinositol pathway and the second messengers I-l,4 ,5-P3 and DAG 
(section 4.1) in the pharmacomechanical coupling of airway smooth muscle. PMA is 
a functional analogue for DAG and competitively inhibits DAG binding at its 
endogenous receptor. Thus PKC is strongly implicated in the development of the 
increase in the contractile response to exogenous and endogeous stimuli. The PMA- 
induced potentiation of response to EFS and to a submaximal dose of ACh was 
therefore examined in rabbit bronchial smooth muscle in the presence of inhibitors of 
PKC.
7.6 Inhibition o f  PKC
A number of substances are known to inhibit PKC but the specificity of most of these is 
not high. Inhibitors currently in use include staurosporine (Tamaoki et al., 1986), 
calphostin (Koybashi et al., 1989), sphingosine (Hannun et al., 1986b), the peptide 
inhibitor ICK-1 and inactive control NICK-1 (House & Kemp, 1987), and H7 (Hidaka & 
Hagiwara, 1987). Of these, H7 and staurosporine are two of the most frequently used.
The isoquinolinylsulfonamide, H7, is commonly employed as an inhibitor of PKC and has 
been described as both potent and specific (Hidaka & Hagiwara 1987; Anwyl, 1989; 
Caramelo et al., 1988; Abdel-Latif, 1986). H7 (10pM) attenuated the phorbol ester-induced 
electrical and contractile changes in the guinea-pig trachea (Souhrada & Souhrada, 1989a) 
and partially reversed PMA-induced changes in aortic smooth muscle (Carmelo et al., 
1988). However it was ineffective in blocking both the contractile and relaxant effects of 
phorbol esters in rabbit trachea (Schramm & Grunstein, 1989). Similarly, in the rabbit 
bronchi preparation H7 produced only a limited attenuation of the response to PKC
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activation by phorbol ester. The inhibitor appeared to dampen the increase in response to 
EFS produced by PMA but had no effect of the potentiation of response to a submaximal 
dose of ACh.
H7 acts at the ATP binding site on the hydrophilic catalytic domain of PKC (Nakadate et 
al., 1988; Ruegg & Burgess, 1989) which has been shown to exhibit a very high degree of 
homology with the ATP-binding sites of several other protein kinases (Edelman et al., 
1987; Hanks et al., 1988); inhibitors acting at this site will not therefore achieve a high 
degree of selectivity. The lack of effect of H7 in our preparation may be due to this lack of 
specificity, to inappropriate incubation time or to a difficulty in penetration of the smooth 
muscle membrane. Species difference may also be important; it is possible that the rabbit 
trachea (Schramm & Grunstein, 1988) and bronchi possess an isozyme of PKC which is 
insensitive to H7. Alternatively, PMA may be producing its effect via mechanisms other 
than the activation of PKC. It was therefore of interest to determine whether a second 
inhibitor of PKC would produce a more pronounced inhibition of the PMA effect in the 
rabbit airway preparation.
Staurosporine, a microbial alkaloid produced by streptomyces, was discovered in 1977 by 
Omura et al and has been shown to counteract the phorbol ester-induced enhancement of 
neurotransmitter release (Daschmann et al., 1988). PKC has been implicated in cell growth 
and replication (Nishizuka, 1986); staurosporine inhibits proliferation of rabbit aorta 
smooth muscle cells (Matsumoto & Sasaki, 1989) and shows strong cytotoxic activity, 
inhibiting the growth of melanoma and leukaemia cells, which may be due to inhibition of 
PKC (Tamaoki et al., 1986); however, staurosporine also inhibited cyclic AMP-dependent 
protein kinase to the same degree as PKC (Tamaoki et al., 1986).
In the rabbit bronchial preparation staurosporine inhibited the PMA-induced potentiation of 
response to EFS, suggesting that the facilitatory effect of the phorbol ester is mediated by 
PKC. However, both staurosporine and H7 inhibit the catalytic fragment of PKC and may
110
not therefore be considered specific inhibitors of the enzyme, although they can be very 
effective in inhibiting reactions thought to be principally mediated by PKC (Garland et al., 
1987; Ruegg & Burgess, 1989). The exact mechanism of action of staurosporine remains 
unknown, however, as its high potency is incompatible with an effect on the ATP binding 
site (Ruegg & Burgess, 1989); thus some unknown factor may be involved in the more 
effective inhibition by staurosporine than by H7 of the PMA-induced potentiation of 
response to EFS in the rabbit airway preparation.
Neither staurosporine nor H7 prevented the potentiation by PMA of the response to 
exogenous ACh. It may be that PMA is acting both pre- and post-junctionally to activate 
PKC, thereby increasing both the amount of neurotransmitter released by nerve stimulation 
and the smooth muscle response to contractile agonists, and that the pre-junctional 
mechanism is more sensitive to inhibitiion by staurosporine or H7. In different tissues 
PKC shows a considerable degree of heterogeneity and the subspecies have different 
kinetic properties and substrate specificities (section 4.4). No data on the effects of PKC 
inhibtors on the different subtypes of PKC are available. Higher concentrations of the two 
inhibitors might produce greater inhibition of the response to ACh. However, at these 
concentrations, enzymes such as cAMP- and CGMP-dependent kinases may also be 
effected (Tamaoki et al., 1986).
Several new compounds have recently become available commercially and may produce 
better, and more specific, inhibition of PKC than has been possible thus far with 
staurosporine and H7; initial studies on a modified staurosporine (Ro-31-8220; Roche 
Products Ltd.) suggest it may be a substantial improvement, as a tool, on these 
compounds. Similarly, Kase and coworkers (1987) report a novel compound, K-252b, to 
be up to three orders of magnitude more potent than the isoquinoline sulfonamide inhibitors 
and to be more selective for PKC than for cAMP-dependent or Ca2+/calmodulin-dependent 
protein kinases. The authors describe the drug as, to their knowledge, "the most potent and 
selective inhibitor for PKC so far reported". However, both these drugs have a similar
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structure to staurosporine and act, like staurosporine and H7, on the catalytic domain. 
Thus, although potent inhibitors of PKC, they may lack the specificity required to be of 
real use in investigating the regulatory role of the enzyme.
As PKC has separate regulatory and catalytic domains (Kishimoto et al., 1983) it is 
possible that compounds acting on the hydrophobic regulatory domain may prove to be 
more specific inhibitors of the enzyme. The protein kinase inhibitors tamoxifen, glossypol, 
trifluoperazine and adriamycin contain lipophilic or non-polar regions which are thought to 
interfere with a hydrophobic interaction between PKC and phospholipid (Nakadate et al., 
1988). They may inhibit the enzyme by interfering directly with the phorbol ester binding 
site on the regulatory domain or with the lipid requirement for binding. It is unclear, 
however, whether or not these compounds will also inhibit Ca2+/calmodulin-dependent 
enzymes (Hidaka & Hagiwara, 1987; Nakadate et al., 1988).
Calphostin C, a microbial compound derived from Cladosporium cladosporioides has 
potent cytotoxic and antitumour activities which might be due to the inhibition of PKC. 
Experimental evidence suggests that it too interacts with the regulatory domain of PKC 
(Kobayashi et al., 1989). In addition, this compound showed inhibitory effects on the 
binding of 3[H]PDBu to PKC and might therefore be much more specific than the other 
available PKC antagonists.
It will be interesting to investigate the effects of these new drugs in the airway preparations 
where they may confirm that the phorbol ester-induced potentiation is mediated by PKC 
and may produce more specific inhibition of PKC than has been possible thus far.
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7.7 Calcium Sensitivity o f the responses
In several smooth muscle preparations the contractile response to ACh is thought to be 
largely independent of extracellular calcium, with the majority of the calcium for contraction 
coming from intracellular stores (Hurwitz et al., 1967; Raeburn et al., 1986). Conversely 
Black et al. (1986) found contraction to histamine and ACh in human bronchial smooth 
muscle to depend on extracellular stores, but reported that only a fraction of the calcium 
entry occurs via voltage-dependent channels. In the rabbit preparation the influx of 
extracellular calcium is important in the response to exogenous ACh; in the absence of 
extracellular calcium the response curve to ACh was shifted to the right. However, 
verapamil attenuated the response to EFS in control tissues suggesting that calcium entry 
through voltage-dependent channels has a role to play in the response to nerve stimulation, 
although it may only be a method of refilling the depleted intracellular stores.
The activity of PKC is regulated by the intracellular calcium concentration. An increase in 
the calcium concentration promotes the association of PKC with the membrane (section 
4.3), and the concentration in the submembrane domain may play a major role in 
modulating the activity of the membrane-associated enzyme. In order to determine the 
contribution of calcium influx from the extracellular space to the PMA-induced potentiation 
of response to EFS and to exogenous ACh in rabbit bronchi, parallel series of experiments 
were run in which the tissues were maintained in low-calcium Krebs or were incubated 
with nifedipine (0.3|iM) or verapamil (10|iM).
The rightward shift o f the ACh response curve in the low calcium environment was 
significantly reduced in the presence of PMA. The phorbol ester appears to halt the 
desensitisation, an effect which may be due to an increase in the calcium sensitivity of the 
contractile proteins via activation of PKC. Similarly, the potentiation of response to EFS by 
PMA is also dependent on the extracellular calcium, as evidenced by the inhibition of the 
phorbol ester effect by the calcium channel blocker verapamil. It is possible that activation
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of PKC by PMA induces calcium influx, directly or indirectly, through voltage-dependent 
channels thereby counteracting the effects of the low calcium environment but remaining 
susceptible to the effects of the calcium channel blockers.
Verapamil and nifedipine block voltage-dependent calcium channels. Nifedipine modulates 
the channel gating by increasing the time constant for the long interval between open bursts 
and effectively plugs calcium channels, reducing their numbers without affecting the 
kinetics of activation or inactivation. In contrast verapamil has no effect on the number of 
calcium channels and appears to affect mainly the rate of activation, inactivation and 
especially recovery after inactivation of the calcium current (reviewed Hurwitz, 1986).
In rabbit secondary bronchi nifedipine prevented the PMA-induced potentiation of the 
response to 10|iM ACh without significantly altering the control response. Verapamil itself 
partially inhibited the control response to ACh but subsequently prevented the potentiation 
of response by PMA. Verapamil also inhibited the potentiation of response to EFS. These 
results contrast with those of Marthan et al (1987), who found no effect of calcium- 
blocking drugs on carbachol-induced tone in human airways, and with clinical reports of a 
lack of effect on resting tone (Cuss & Barnes, 1985; Williams et al., 1981) and on 
cholinergic-induced bronchoconstriction (Roberts et al., 1986; Matthews et al., 1983). 
However, calcium channel-antagonists produced a relaxation of human bronchus in vivo 
(Popa et al., 1984), and in vitro prevented contraction to low concentrations of ACh in 
canine tracheal smooth muscle (lnM -lpM ; Farley & Miles, 1978) and produced partial 
inhibition of higher doses of cholinergic agonists in human tissue (Horio et al., 1984; 
Raebum et al., 1986; Roberts et al., 1986) demonstrating a degree of variability in efficacy 
of calcium channel antagonists in different preparations.
Nevertheless, the results suggest that, in rabbit bronchial smooth muscle, the PMA effect is 
largely dependent on the influx of extracellular calcium through voltage-dependent 
channels. The dependence of the contractile response to phorbol esters on the influx of
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extracellular calcium has been reported in several tissue preparations (Danthuluri and Deth, 
1984; Forder et al., 1985; Park & Rasmussen, 1985; Schramm & Grunstein, 1989; 
Souhrada & Souhrada, 1989a); in all cases the phorbol ester response could be attenuated 
by removal of calcium from the bathing solution or by blocking calcium channels. Evidence 
obtained in brain tissue suggests that PMA increases both the influx of calcium and its 
accumulation in the cell (section 7.4).
The fact that the PMA potentiation can be so effectively inhibited by nifedipine and 
verapamil suggests a direct role for activated PKC in the regulation of calcium channels. 
Spedding (1987) investigated this possibility but found no evidence for such control of 
channel function in rat aorta or guinea pig taenia coli, considering it more likely that 
activated PKC influenced the influx of calcium indirectly via changes in calcium extrusion 
or cellular depolarisation in these preparations. However, there is no reason to believe that 
the same control system exists in all smooth muscles; Schramm & Grunstein (1989) 
observed a PKC-dependent facilitation of calcium influx through voltage-dependent 
channels in rabbit tracheal smooth muscle while Park & Rasmussen (1985) and Forder et 
al. (1985) note a potentiation of the effect of PMA by the calcium channel agonist BAY- 
K8644 in airway smooth muscle.
Thus, although several mechanisms may contribute to the potentiation process in airway 
smooth muscle, blocking calcium entry was completely effective in removing the PMA 
effect. Forder et al. (1985) postulate that calcium influx through voltage-gated channels 
acts principally to raise the cytosolic calcium concentration in a restricted domain just under 
the plasma membrane rather than in the bulk cytosol, resulting in up-regulation of 
membrane-bound PKC. It is possible that PKC is not fully active without high calcium 
concentrations in this submembrane region. Thus, inhibition of calcium entry into this 
domain may attenuate the activation of the enzyme and abolish subsequent effects such as 
stimulation of the Na+-H+ antiport (section 7.8).
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There is, therefore, evidence that stimulation of PKC in bronchial smooth muscle leads to 
calcium influx through nifedipine- and/or verapamil-sensitive channels. However, at the 
concentrations employed in these studies, these actions do not lead to contraction in the 
absence of an agonist or neurotransmitter. PMA could place PKC in a state of activation 
which is dependent on co-activation with calcium and which may be insufficient to initiate 
contraction itself but could be effective in enhancing subsequent receptor-mediated 
contraction.
7.8 Possible mechanism o f  action
A. Modulation o f ion flux
It has been proposed that PKC plays a role in the extrusion of Ca2+ immediately after its 
mobilisation into the cytosol, e.g. following receptor stimulation, and that the Ca2+- 
transport ATPase is a possible target for PKC (Nishizuka, 1986). These hypotheses are 
substantiated by the fact that addition of phorbol esters to various cell types frequently 
produces a decrease in cytosolic [Ca2+] concentration (Drummond et al., 1985; Albert & 
Tashjian, 1985). However, other evidence suggests that PKC may also be involved in the 
enhancement of Ca2+ entry (DeRiemer et al., 1985; Albert & Tashjian, 1985; Farley & 
Auerbach, 1986; Wakade et al., 1986).
Calcium influx into the submembrane domain could produce a high local calcium 
concentration which would maintain PKC in an active state and could result in the PKC- 
induced potentiation of Ca2+ influx and efflux. Measurement of the intracellular calcium 
concentration is usually made in the bulk cytosol. It is possible that the efflux of calcium 
caused by the PKC-induced increase in calcium-pumping keeps the cytosolic calcium levels 
low but that the concentration can reach very high levels beneath the membrane thus 
keeping PKC active (positive feedback) as long as the stimulus is maintained.
B. Mediator release
An increase in the production of arachidonate or its metabolites, some of which are 
potent bronchoconstrictors, particularly in the peripheral airways where they are as 
potent as histamine (Schneider & Drazen, 1980), could contribute to the increased 
responsiveness of bronchial smooth muscle in the presence of PMA. Such a 
mechanism appears to operate in human umbilical vein epithelial cells, in which 
PMA enhanced production of PGF2ot, PGE2 and PGD2 (Zavoico et al., 1990).
The release of arachidonate and the synthesis of eicosanoids is related to agonist- 
induced phosphatidyl inositol turnover in several tissues. Phosphatidyl inositol and 
the poly-phosphoinositides are rich in arachidonate at the 2-position of glycerol 
(Majerus et al., 1988; Mitchell, 1975) and agonists shown to stimulate the release 
of arachidonate include muscarinic cholinergic agonists, a 2-agonists, serotonin, 
angiotensin n ,  substance P and E G F .  These agonists also all produce activation of 
PKC.
PMA stimulates release of arachidonate and/or eicosanoids in several cell types 
including mast cells, macrophages and epidermal cells (Jacobson et al., 1987; 
Emilsson & Sundler, 1986; Ohuchi et al., 1985) and potentiates agonist- and 
calcium ionophore-induced release of arachidonate in platelets (Halenda & Rehm, 
1987; Halenda et al., 1985) indicating a synergism between PKC-activation and the 
rise in intracellular calcium.
Arachidonate and its eicosanoid derivatives produce activation of PLC in intact cells 
(Zeitler & Handwerger, 1985), and several arachidonate products, particularly 
lipoxin A, activate PKC and may also be involved in the modulation of its substrate 
specificity (Nishizuka, 1988; Hansson et al., 1986), thus providing a possible 
positive feedback loop on the enzyme that initiated arachidonate production.
Indomethacin inhibits the activity of cyclo-oxygenase and thus prevents the 
production of thromboxanes and prostaglandins from arachidonate. In rabbit 
bronchial smooth muscle pre-incubation with indomethacin had no significant effect 
on the potentiation of response to exogenous ACh by PMA. While it is possible 
that, in this preparation, the effect of PMA was mediated by the lipoxygenase 
degradation products of arachidonate alone, these results indicate that the cyclo- 
oxygenase products of arachidonate metabolism do not play an important role in the 
increased response to cholinergic stimuli.
Indomethacin itself increased the response to a single submaximal concentration of 
ACh by a small but significant amount. This potentiation could be due to the 
removal of an inhibitory arachidonate-derived cyclo-oxygenase product(s) which 
previously functioned as a brake on exaggerated bronchoconstrictor responses to 
cholinergic stimuli. Two cyclo-oxygenase products of arachidonate metabolism, 
prostacyclin and PGE2, have been shown to inhibit phosphatidylinositol 
breakdown and the generation of inositol phosphates (Lapetina, 1984; Takenawa et 
al., 1986); thus, incubation with indomethacin would prevent their usual negative 
modulation of the contractile process.
C. Activation o f exchange mechanisms.
Souhrada and Souhrada (1989a) report that amiloride, one of the most specific and 
potent inhibitors of sodium entry, abolished the response of rabbit tracheal smooth 
muscle to phorbol esters and that the response was similarly abolished in low 
sodium. Findings in other smooth muscle cell systems (Besterman & Cuatrecasas, 
1984; Rossoff et al., 1984; Gelfand et al., 1987) confirm that phorbol esters 
stimulate Na+-H +  exchange, resulting in sodium influx. This mechanism 
contributes to the regulation of intracellular pH in muscle fibres (Benos, 1982) and 
has been found in vitro to provide a substrate for PKC (Bums & Rozengurt, 1983; 
Rossoff et al., 1984; Moolenaar et al., 1984)
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Stimulation of sodium influx might therefore be involved in the phorbol ester- 
induced potentiation of response to contractile stimuli and it was decided to study 
the effect of amiloride in the rabbit bronchial preparation. At a concentration that has 
been shown to exhibit near maximal inhibition of sodium transport across cell 
membranes (10|iM; Benos, 1982), amiloride had no significant effect on the control 
responses to exogenous ACh but attenuated the PMA-induced potentiation. These 
results are consistent with the hypothesis that PKC activation in bronchial smooth 
muscle leads to increased activity of Na+/H+ exchange. This would increase the 
intracellular sodium concentration which could in turn result in calcium influx via 
N a+/C a2+ exchange, as postulated by Danthuluri and Deth (1984), and may 
therefore contribute to subsequent enhancement of responses to contractile stimuli.
However, the attenuation of the PMA-induced potentiation may have been due to a 
direct effect of the amiloride on plasma membrane ion channels or on PKC itself. 
Besterman et al. (1985) and Kleyman & Cragoe (1988) report that amiloride 
(0.1|iM-lmM) inhibits PKC-mediated protein phosphorylation in vitro, and inhibits 
the voltage-dependent calcium channel of porcine heart sarcolemma vesicles with an 
IC50 of 90|iM. Full elucidation of the role of Na+/H+ exchange in phorbol-ester 
mediated potentiation of response will become possible with the development of 
structural analogues of amiloride with increased affinity for a particular transport 
system (Kleyman & Cragoe, 1988).
D. Phosphorylation o f cellular proteins
While the results of many groups indicate that PKC activation results in a slowly 
developing contractile response in tracheal and vascular smooth muscle (section 7.1), those 
obtained in the rabbit and human preparations suggest that PKC can play a role in agonist- 
induced responses; the contractile responses to both EFS and exogenous ACh were 
diminished in the presence o f the PKC inhibitors H7 and staurosporine. These 
observations are substantiated by detailed intracellular measurements o f protein
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phosphorylation made by Rassmussen et al. (1987). This group recorded temporal changes 
in the pattern of protein phosphorylation induced by carbachol in tracheal smooth muscle 
and compared them with the pattern produced when contraction was initiated by the 
phorbol ester PDBu. They found that addition of carbachol produced phosphorylation of 
myosin light chain in less than 60 seconds, followed by a dephosphorylation to basal levels 
over 20 minutes, accompanied by a progressive rise in the phosphorylation of another 
group of cellular proteins which was subsequently maintained. These proteins included a- 
and p-desmin, synemin, caldesmon and four small, 18-30kDa, unidentified proteins). In 
contrast, addition of the phorbol ester, PDBu, resulted in a very gradual contraction over 
60 minutes which reached 60% of the carbachol induced tone. At the 60 minute time point 
there was an increase in phosphorylation of the same group of late-phase proteins as seen 
60 minutes after carbachol addition. No sustained contraction to carbachol or to PDBu, or 
phosphorylation of the late phase proteins was observed if extracellular calcium was 
removed prior to the addition of the agonists.
The above results suggest that PKC is implicated in late-phase protein phosphorylation 
during normal agonist action in these preparations. Via these mechanisms, inappropriate 
activation of PKC could produce an increase in response to endogenous and exogenous 
agonists.
7.9 Conclusions
The results o f this study demonstrate that incubation with phorbol esters can enhance 
responses of airway smooth muscle to endogenous contractile agonists and suggest that 
this effect is mediated via activation of PKC. The findings, therefore, support the 
hypothesis of Obianime et al. (1989) that inappropriate activation of PKC in smooth 
muscle cells may contribute to the pathogenesis of airway hyperreactivity in asthma. 
Clearly PMA-induced sustained activation of airway PKC can result in exaggerated 
responses to calcium mobilizing agonists and this increase is at least in part due to
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increased fluxes of calcium and sodium ions, and independent of prostaglandin 
production.
An alteration in the pattern or extent of PKC activation in vivo is therefore a possible 
mechanism for the enhanced response of airway smooth muscle, in diseases such as 
allergic asthma, to substances that stimulate the turnover of inositol phospholipids in their 
stimulus-contraction coupling. While the importance of the potentiation of response to 
ACh and histamine in the airways is obvious, many other airway spasmogens utilize this 
pathway and an abnormality in intracellular coupling would therefore produce altered 
responses to a wide range of mediators including substance P, serotonin, vasopressin 
and bradykinin as well as endothelin and platelet derived growth factor which are 
currently attracting much interest.
7.10 PKC and airway sensitisation
The conclusion from these studies, that PKC may be involved with bronchial 
hyperreactivity, is particularly interesting in the light of recently published results which 
suggest that exposure of airway smooth muscle cells to specific reaginic IgG! can activate 
airway PKC and that this activation is intimately involved in the response to specific 
antigen. Souhrada & Souhrada (1989b) report that the addition of IgGj to the trachea of 
sensitised guinea pigs produces characteristic electrical and contractile changes in the 
smooth muscle: an initial depolarisation and increase in the isometric force. The changes 
were very similar to those obtained after administration of phorbol ester (Souhrada & 
Souhrada, 1989a). Thus these workers suggested that the addition of IgGj may directly 
stimulate PKC (although it is possible that IgGj may act indirectly by stimulating 
turnover of inositol phospholipids and the generation of DAG). Preincubation with H7 
inhibited the response to IgGj substantiating the probable involvement of PKC. 
Similarly, oral administration of another PKC inhibitor K-252a to guinea pigs resulted in
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partial but significant inhibition of anaphylactic bronchoconstriction (Ohmori et al., 
1988).
Thus it would appear that PKC is activated by specific antigen, is involved in the 
anaphylactic response and that sustained activation can result in exaggerated responses to 
endogenous mediators. As the response to specific antigen can be blocked by inhibitors 
of PKC, it is possible that the development of more specific PKC inhibitors may produce 
a novel and effective therapy for in vivo intervention in disease states such as allergic 
asthma. In this context it is of interest that sodium chromoglycate, a potent antiasthmatic 
agent of unknown action (Rafferty & Holgate, 1988; Warner, 1988), can inhibit PKC 
activity (Lucas & Schuster, 1987).
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